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Abstract
Nuclear spin polarization can be significantly increased through the process of hyperpolarization, 
leading to an increase in the sensitivity of nuclear magnetic resonance (NMR) experiments by 4–8 
orders of magnitude. Hyperpolarized gases, unlike liquids and solids, can be more readily 
separated and purified from the compounds used to mediate the hyperpolarization processes. 
These pure hyperpolarized gases enabled many novel MRI applications including the visualization 
of void spaces, imaging of lung function, and remote detection. Additionally, hyperpolarized gases 
can be dissolved in liquids and can be used as sensitive molecular probes and reporters. This mini-
review covers the fundamentals of the preparation of hyperpolarized gases and focuses on selected 
applications of interest to biomedicine and materials science.
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1. Introduction
The use of techniques to enhance nuclear spin polarization (P) to order unity (i.e. nearly 
100%) results in corresponding gains in NMR sensitivity by 4–8 orders of magnitude.[1] 
This process of significant polarization enhancement—well above that achieved at thermal 
equilibrium—is termed hyperpolarization. Hyperpolarization of solids, liquids, and gases[2] 
has been demonstrated via a number of techniques including Brute Force Polarization 
(BFP),[3] Spin Exchange Optical Pumping (SEOP),[4] Dynamic Nuclear Polarization 
(DNP),[1c] Chemically-Induced Dynamic Nuclear Polarization (CIDNP)[5] photo-CIDNP,[6] 
Parahydrogen Induced Polarization (PHIP),[7] and Signal Amplification By Reversible 
Exchange (SABRE).[8]. A wide range of nuclei can be directly hyperpolarized, 
including 1H,[9] 3He,[10] 7Li[11], 13C,[1c, 12] 15N,[13] 19F,[14] 31P,[15] 83Kr,[16] and 129Xe,[4, 17] 
among others.[18] Hyperpolarized (HP) substances are revolutionizing the fields of NMR 
spectroscopy and magnetic resonance imaging (MRI), because many applications that were 
previously impractical because of weak NMR signals (e.g. metabolites at sub-mM) are now 
becoming possible. Moreover, the enormous gain in attainable SNR allows spectroscopic 
detection and imaging of HP compounds to be performed in seconds, obviating the need for 
time-consuming signal averaging and thermal recovery of the spin magnetization. The 
ability to rapidly acquire signals with very high SNR from HP systems is the inherent 
feature that is greatly desirable for in vivo gas imaging applications: i.e. images can be 
acquired during a single breath hold; sufficient signal can be attained despite low density of 
gas compared to liquid. While liquid HP contrast agents are injected in vivo to probe 
metabolism[19] (extensively discussed in many recent reviews)[20] or used otherwise,[21] they 
typically cannot be used to probe gas-phase processes in vitro or in vivo. This mini-review 
focuses on the techniques allowing the production of HP gases with particular application to 
their use in biomedical applications, and explores some examples from materials science.
We begin with the fundamentals of SEOP in the context of NMR hyperpolarization of 129Xe 
gas. Although other noble gases have been hyperpolarized, none are as widely used for 
magnetic resonance as HP 129Xe, which has a relatively large natural abundance (ca. 26%) 
and is relatively cheap (ca. $20/L). The selected applications described here include 
functional lung imaging,[22] metabolic brown fat imaging,[23] and biosensors[24] (including 
those enabled by genetic encoding[25]). A recent demonstration of the DNP process to 
hyperpolarize 129Xe[26] and hydrocarbon gases[27] is also described.
HP gases can also be efficiently produced via PHIP, when parahydrogen gas is added in a 
pairwise manner to a multiple chemical bond (C=C or C≡C) in an unsaturated molecule—
resulting in a gaseous HP product. This process can be performed in heterogeneous 
fashion,[9a, 28] and despite low T1 of the HP states, this powerful scalable technique allows 
for cheap preparation of HP hydrocarbons on demand. Moreover, because protons are being 
directly hyperpolarized and detected, it is inexpensive and straightforward to perform (since 
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expensive isotopic enrichment and heteroatoms-specific instrumentation can be obviated) 
and thus is readily applied with conventional clinical MRI scanners. This mini-review 
describes the fundamentals of PHIP for production of HP gases,[29] selected recent 
developments to extend the lifetime of the HP state through the use of the long-lived spin 
states (LLSS),[30] and HP gas application for void space imaging, remote sensing, time of 
flight imaging, and micro-fluidic imaging.
In all cases, the separation from other compounds required for hyperpolarization process 
(e.g. Rb in case of SEOP of HP 129Xe, un-paired radicals in the case of DNP, and 
homogeneous or heterogeneous catalysts in the case of PHIP) is well known, and 
experiments can be performed with HP gases in a chemically pure form.
2. Fundamentals of Noble Gas Hyperpolarization
2.1. SEOP
The most commonly employed method for generating HP noble gases is spin-exchange 
optical pumping (SEOP). The development of SEOP is rooted in the pioneering work of 
Kastler,[31] who was recognized with the Nobel Prize in physics for demonstrating that 
electronic spin order can be created in alkali metal vapors using circularly polarized laser 
light. Later Bouchiat, Carver, and Varnum[32] showed that the addition of 3He to the gas 
mixture permitted helium nuclear spins to be polarized by spin-exchange collisions with the 
optically pumped alkali vapor atoms—work that was extended to 129Xe by Grover.[33] The 
rich physics of SEOP has been extensively explored by Happer, Cates, Chupp, Walker, and 
many others (e.g. Refs. [4, 17b, 34]), ultimately leading to the ability to produce large 
quantities of HP noble gases with nuclear spin polarization levels approaching unity for use 
in a variety of applications—including those described throughout this Mini-Review.
The underlying phenomenon of SEOP has been reviewed extensively elsewhere,[4, 35] but 
can be briefly described as follows (Figure 1): First, a heated alkali metal vapor is irradiated 
with resonant circularly polarized light. Angular momentum conservation results in 
population being driven from appropriate spin-state ground states (e.g. mJ=−1/2 with σ+ 
light, neglecting nuclear spin degrees of freedom). The ground state levels are repopulated at 
roughly the same rates, resulting in depletion of one spin state and population accumulation 
in the other—rendering the alkali metal vapor electronically spin polarized. Gas-phase 
collisions then transfer polarization from the electrons of the alkali metal to the spins of the 
noble gas nuclei via Fermi-contact interactions. This process is allowed to continue so that 
the nuclear spin polarization can accumulate over time, ultimately yielding a steady-state 
nuclear spin polarization given by:
where 〈PAM〉 is the spatially averaged polarization of the alkali metal vapor, ΓN is the noble 
gas nuclear longitudinal relaxation rate (1/T1) in the optical pumping cell, and γSE is the 
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spin-exchange rate (i.e., the rate at which polarization can be transferred from alkali metal to 
the noble gas).
Although the vast majority of SEOP experiments have employed the spin I=1/2 noble gas 
isotopes 129Xe and 3He, the quadrupolar species 21Ne (I=3/2),[37] 83Kr (I=9/2),[38] 
and 131Xe[39] (I=3/2) can also be polarized via this method. For the alkali metal vapor, Rb is 
most-commonly employed for practical reasons—including its low melting point[40] 
(facilitating vaporization) and the availability of high-powered lasers resonant with its D1 
transition[41]; however, K and Cs are also utilized (particularly for 3He[42] and 129Xe,[43] 
respectively).
Technological developments for SEOP have been extensively reviewed elsewhere,[35] and 
only a brief description is given here. Devices for preparing HP noble gases may be grouped 
into two types: “stopped-flow” and “continuous-flow”. In a stopped-flow device,[44] a batch 
of a desired gas mixture is loaded into an OP cell (which contains a quantity of AM) and is 
heated and optically pumped with a laser; once the gas is hyperpolarized, OP is stopped and 
the gas is transferred to the sample (usually after the cell has cooled to condense the AM); 
alternatively, multiple batches may be systematically polarized and collected to accumulate 
the HP gas prior to transfer. In a continuous-flow device,[45] a desired gas mixture is allowed 
to flow from its source continuously through a heated cell while it is irradiated by the laser; 
the flow rate is chosen to allow sufficient average residency of noble gas atoms in the cell to 
enable the gas to be hyperpolarized “on the fly”. The HP gas mixture can then either be 
directed into the sample or a cryo-condenser (to collect the otherwise-dilute HP noble gas 
and deliver it purely and with high density, following sublimation[45a]).
All of the noble gas isotopes are amenable to the stopped-flow design[39, 44h, i, 46], whereas 
the relatively high spin-exchange rates and facile cryo-storage of 129Xe’s polarization[47] 
make it the best choice for use in a continuous-flow device. Both device designs have 
evolved considerably over the years, achieving ever-greater gas polarizations and production 
amounts/throughputs—benefiting in particular from the advent of compact, high-power, 
relatively low-cost light sources embodied by spectrally-narrowed laser diode 
arrays.[41, 44e, g, 45f, 48]
2.2. Other Methods for Hyperpolarizing Noble gases: MEOP, “Brute Force”, and DNP
In addition to SEOP, HP noble gases can be prepared by metastability exchange optical 
pumping (MEOP), “brute force”, and dynamic nuclear polarization (DNP), and we briefly 
describe these approaches here.
In MEOP,[49] an electrical discharge is used to create metastable (electronically excited) 
atoms in a dilute gas. The unpaired electrons of these metastable atoms can be spin-
polarized via optical pumping with a laser. The angular momentum of the electron spin may 
then be transferred to the nuclear spin of another gas atom in the cell during a metastability-
exchange collision. The process is allowed to continue until a bulk nuclear spin polarization 
develops across the cell. Finally, a pump is used to compress the HP gas to a sufficient 
density prior to use.[50] MEOP works well for 3He[49] and has been highly effective at 
producing clinical-scale amounts for biomedical imaging experiments (e.g. [51]); MEOP is 
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generally less effective for the heavier noble gas isotopes because of stronger relaxation 
mechanisms.[52]
Next, to understand the so-called brute-force (BF) approach, one should first consider the 
relation determining the equilibrium (“thermal”) nuclear spin polarization (for I=1/2 nuclei):
where γ is the nuclear gyromagnetic ratio, B0 quantifies the strength of the magnetic field, T 
is the absolute temperature, ħ is Planck’s constant divided by 2π, and k is Boltzmann’s 
constant. At room temperature and in a typical superconducting magnet,  will be ~10−5–
10−6. Thus, if the sample temperature were lowered to milli-Kelvin temperatures (and 
enough time were allowed for the nuclear spins to relax to their new equilibrium conditions), 
the nuclear spin polarization would exceed 10%. Although the approach can be time 
consuming, such BF approaches have used 3He/4He dilution refrigerators to polarize the 
nuclear spins in different substances, including noble gases.[53]
Finally, noble gases can also be hyperpolarized via DNP.[54] Here, the approach is 
essentially the same as that of dissolution DNP (d-DNP), introduced by Golman and co-
workers in 2003.[1c] Briefly, the approach requires the substance to be hyperpolarized 
(here, 129Xe) to be mixed in a glassy frozen matrix containing molecules with unpaired 
electron spins (e.g., a stable radical or a photoinduced, non-persistent radical[54c]). With the 
matrix placed at very low temperatures (~1 K) and at high magnetic field (several T), the 
unpaired electrons obtain a near-unity spin polarization. The matrix is then irradiated with 
microwaves in order to drive the high spin polarization to surrounding nuclei in the matrix, 
allowing a high bulk nuclear spin polarization to accumulate over time. The matrix is then 
rapidly warmed, sublimating the HP xenon as a pure gas—hence the name “sublimation 
DNP” given for this approach.[54b] Using DNP, polarization values of ~30% have been 
achieved in ~1.5 hr,[54b] despite identified issues with a spin-diffusion bottleneck between 
electron and 129Xe spins.[54a] Although the amounts and polarization values achieved thus 
far with DNP are not as high as corresponding values achieved with SEOP, the advantages 
are the increasing availability and general applicability of dissolution DNP polarizers in 
biomedical facilities—including Oxford’s HyperSense[1c] and more recently, GE 
Healthcare’s SPINlab.[55]
2.3. The Rise of Magnetic Resonance Applications of Hyperpolarized Noble Gases
Prior to finding their way into magnetic resonance, HP gases found their first applications in 
fundamental physics experiments (work that of course continues, see for example, 
Refs. [56],[57]). And although the portions of this Mini-Review that are dedicated to HP noble 
gases are largely concerned with biomedical applications of 129Xe, the first MR applications 
actually involved studies of materials (as well as investigations of the use of HP 129Xe as a 
source of hyperpolarization for other spins).
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Soon after the demonstration of ultra-long 129Xe relaxation times for frozen solid xenon,[47] 
Pines and co-workers used HP 129Xe NMR to probe the surfaces of powdered 
substances[44a] (and high-field gas-phase spectroscopy was also demonstrated by performing 
SEOP within an NMR magnet[43a]). Soon afterwards, the exquisite sensitivity of the 129Xe 
chemical shift was investigated for probing surfaces of a number of porous materials and 
particles[58]—as was the ability to transfer the 129Xe hyperpolarization to the nuclear spins 
of other substances.[59] The advent of continuous-flow production of HP 129Xe[45a] was 
soon applied to greatly facilitate studies of materials surfaces,[60] including under conditions 
of magic angle spinning.[61] Since that work, HP xenon has been used to study diffusion in 
confined spaces or porous media[62],[63],[64]; image such systems as a function of gas 
flow[65] or 129Xe chemical shift[66]; or spectroscopically probe single-crystal surfaces[67], 
liquid crystals,[68] or combustion processes.[69] However, the greatest body of materials-
related work has concerned the effort to probe void spaces and surfaces in microporous or 
nanoporous materials with HP 129Xe, thereby providing information about pore size, pore 
shape, and gas dynamics in: nanochanneled organic, organometallic, and peptide-based 
molecular materials[70] (including in macroscopically oriented single crystals[71]); multi-
walled carbon nanotubes[72]; gas hydrate clathrates[73]; porous polymeric materials and 
aerogels[74]; metal-organic frameworks[75]; calixarene-based materials and nanoparticles[76]; 
organo-clays[77]; mesoporous silicas[78]; and zeolites and related materials[79] — efforts that 
have been aided by computational studies of xenon in confined spaces (e.g., Refs. [80]). For a 
more in-depth review of HP 129Xe in microporous and nanoporous materials, see Ref. [81].
Indeed, 129Xe has found the widest NMR/MRI application of the HP noble gases—a fact 
that is at least partially due to its significant natural abundance (26.44%) and ready 
recoverability from air during oxygen production. While 3He does have the advantage of a 
roughly three-fold greater gyromagnetic ratio, its weak chemical shift dependence and lack 
of significant interaction with other substances make it a poor probe of other substances. 
More importantly, the lack of natural abundance (most 3He comes from tritium decay) will 
limit the future use of this isotope for wide-scale magnetic resonance applications.[82] The 
rapid relaxation suffered by the quadrupolar isotopes (21Ne, 83Kr, and 131Xe) presents a 
challenge for most HP NMR applications, although as pointed out by Meersmann and co-
workers, the quadrupolar interaction also endows a unique sensitivity of HP 83Kr to surface 
chemistry and local geometry that can be complementary to the information provided 
by 129Xe chemical shift – a feature that can prove useful for probing porous materials, lung 
tissues, and other systems.[38, 69b, 83]
3. Clinical Application of Hyperpolarized Xenon-129 MRI
HP xenon-129 MRI (129Xe-MRI) is an MRI modality first developed in 1990s for enhanced 
lung imaging of ventilation and perfusion and regional information on gas exchange. It has 
been used to image patients with a number of respiratory diseases, including asthma, COPD, 
and pulmonary fibrosis. In addition to its use in disease assessment and long-term 
management, in vivo gas-phase 129Xe-MRI has the potential to provide imaging biomarkers 
of drug efficacy, which could be used to stratify treatment, improve patients’ quality of life, 
and cut down healthcare costs. It can also be potentially employed by pharmaceutical 
companies to speed up decision-making in proof-of-concept studies in drug development.
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3.1. From Mice to Men
Identified by British chemists William Ramsay and Morris Travers in 1898[84] (following 
their discovery of neon and krypton a few months beforehand), xenon is a colorless and 
odorless noble gas. Xenon initially captured the attention of clinicians as a general 
anesthetic agent when Albert Behnke, a US Navy physician, investigated the cause for 
‘drunkenness’ observed in deep-sea divers.[85] Interestingly, Behnke also happened to be the 
clinician who had studied the anesthetic effects of nitrogen and helium in humans.[86] It was 
Lawrence et al.,[86] who first published experimental data on the general anesthetic effects of 
xenon with mice as their test subjects. It took clinicians 5 years to put xenon to use in 
clinical settings,[87] and xenon has continued to be used as a general anesthetic since.
3.2. The Motivation for Hyperpolarized Xenon-129 MRI
The next major clinical application of xenon-129 came in 1994 in the form of its use as an 
inhalational contrast agent for magnetic resonance imaging (MRI).[88]
Plain radiograph and computed tomography (CT) are currently the main modalities used to 
image the lungs in clinical settings. Despite their ability to provide detailed anatomical data, 
in particular with high resolution CT, their main drawbacks are the risks involved with 
repeated radiation exposure and the inability to provide physiological information on 
regional lung function. Although conventional MRI has been a game-changer in both neuro 
and hepatic imaging, its dependence on the protons of water molecules in tissue to provide 
nuclear magnetic resonance (NMR) signal[88] has meant that it is of little value in imaging 
the lungs due to poor image quality because of three factors: 1- low proton abundance within 
the lung parenchyma, 2- air-tissue interface causing magnetic field heterogeneity, and 3- 
image degradation secondary to cardiac and respiratory motion.[89]
The NMR signal strength of a given species depends on its nuclear spin, i.e. polarization, 
and the volume of the element. Except for those in water and fat, the concentrations of all 
other protons and nuclear species are too low to be of use in conventional MRI. However, 
hyperpolarization can be used to overcome the otherwise low detection sensitivity for low-
concentration spins. For example, by delivering HP 129Xe to excised mouse lungs, Albert 
and colleagues were able to obtain improved MR lung images compared to those obtained 
with conventional MRI.[88]
3.3. Hyperpolarized Xenon-129 MRI — There and Back Again
HP xenon-129 MRI of human lungs, which are obviously much larger than those of mice, 
proved challenging; it took physicists three years following Albert’s paper in 1994 to be able 
to publish data on human studies.[90] The challenge was due to the need to produce much 
larger quantities of HP 129Xe and to achieve adequate levels of polarization. Furthermore, 
conventional MR imaging sequences had to be modified as the polarization of the noble gas 
is non-renewable, and some polarization is lost every time an MR excitation pulse is 
applied.[91] These issues led to a shift in interest from 129Xe to helium-3 (3He), a fellow 
noble gas, whose larger gyromagnetic ratio and larger achievable polarization compared 
to 129Xe at the time allowed for better signal intensity and image resolution for a given 
amount of HP gas.[92]
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Interest in 129Xe was reignited in the early 2010s; this resurgence was due to the fact that 
contrary to 129Xe, which is naturally occurring, 3He is a byproduct of tritium decay. 3He had 
become scarce as the US sequestered 3He for 3He-based neutron detectors for national 
security, leading to extremely low availability of 3He for scientific research and an 
exponential rise in its price.[92b] As a result, it was unlikely that 3He-MRI would become a 
routine imaging modality in clinical settings, and so interest in 129Xe-MRI was rekindled.
3.4. Safety & Tolerability Profile in Patient Groups
Over the past two decades, 129Xe-MRI has been improved and utilized in imaging a wide 
range of respiratory diseases, including asthma,[93] chronic obstructive pulmonary disease 
(COPD),[93b, 94] cystic fibrosis (CF),[93a] and pulmonary fibrosis.[95] Studies specifically 
designed to investigate the safety and tolerability of 129Xe-MRI have not shown major 
common side effects in various patient groups, including those with asthma,[93a] and mild-
moderate COPD,[93a, 96] with light-headedness of very short duration as the main reported 
minor side effect.
3.5. Ventilation Imaging
Ventilation imaging provides valuable clinically relevant information relevant to regional 
lung function. Regions with normal ventilation typically appear bright and homogenous 
on 129Xe-MRI, and in a healthy subject with normal lung function, both lungs show 
relatively homogenous ventilation except for two regions (as seen in Figure 2 and discussed 
in Figure 2 caption). In those with diseased lungs where regional ventilation is impaired, the 
abnormal regions will appear darker; these regions are called ‘ventilation defects’.
Compared to healthy volunteers, 129Xe distribution has been shown to be regionally 
heterogeneous with ventilation defects in a number of different patient groups, including 
those with asthma, COPD, and CF.[93a, 94c, d] Ventilation imaging has also been shown to 
correlate with spirometry [94c] and CT findings [97] in patients with COPD.
Additionally, ventilation imaging has been used to try and assess the efficacy of drug 
therapy. Studying the impact of salbutamol in patients with asthma, Parragra’s group [93b] 
has reported a significant reduction in ventilation defects after salbutamol administration.
Hence 129Xe-MR ventilation imaging, although appearing simple, can be used to not only 
assess disease, but to also assess drug efficacy and monitor disease progression.
3.6. Diffusion Imaging
The apparent diffusion coefficient (ADC) of gas within lung is a function of alveolar size 
and geometry. This can be assessed using 129Xe-MRI to characterize pulmonary 
microstructure at the alveolar level, as seen in Figure 3.
129Xe-MRI derived ADC mapping has been shown to correlate well with pulmonary 
function tests,[94d, 96] including total diffusing capacity for the lung (TLco). This is of 
important clinical significance, as it clearly illustrates the ability of 129Xe-MRI to provide 
regional quantitative lung function data. In addition to its potential use in disease diagnosis, 
monitoring and assessing therapeutic drug efficacy, diffusion imaging can also be used to 
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plan surgery, including tumor resection and lung volume reduction surgery for emphysema, 
as it can aid prediction of post-surgery lung function. The predicted post-surgery lung 
function is currently calculated using ventilation or perfusion scintigraphy and quantitative 
CT; however, there is a risk that scintigraphy, the most commonly used imaging modality, 
may underestimate post-operative lung function,[98] thereby, preventing the patient from 
undergoing potentially curative surgery.
3.7. Dissolved Phase Imaging
129Xe (in contrast to 3He) is highly lipophilic and soluble in biological tissues and thus is 
able to provide information on gas exchange and pulmonary perfusion particularly 
interesting in the context of functional lung imaging.[99] It is the associated persistent 
exchange of 129Xe between the gas and dissolved compartments, each with its own different 
resonance frequencies, that is central to assessing gas exchange using 129Xe-MRI.[100] 
Therefore, combined imaging of the gas phase 129Xe and the dissolved phase 129Xe would 
permit ventilation/perfusion (V/Q) imaging—and consequently a more direct mapping of 
lung function.[88] Hence, although 129Xe-MRI initially lagged behind 3He-MRI, 
developmentally, 129Xe-MRI is likely to be the pragmatic HP noble gas MRI modality of 
choice.
Although the majority of the inhaled 129Xe remains in the airspaces, where it exhibits its 
primary gas-phase resonance, a portion dissolves in alveolar septa and crosses the alveolar-
capillary barrier to dissolve in the blood. The resulting shift in the resonance frequency leads 
to the appearance of two additional distinct resonances: 1- the barrier resonance, and 2- the 
hemoglobin-associated 129Xe resonance, as seen in Figure 4 (We note the intensity 
differences between the two spectra are due primarily to the variation in the amount and 
speed at which hyperpolarised xenon gas was inhaled by the two volunteers. As volunteers 
became more familiar with the breathing protocol, the improvements in both ventilatory 
image quality and dissolved phase signal/noise were noted). This transfer pathway is 
identical to that followed by oxygen; therefore, in addition to being a ventilation 
probe, 129Xe is also a gas diffusion transfer probe.[95a]
The signal intensity of the dissolved phase 129Xe is approximately 2% of that remaining in 
the alveolar spaces, which presents a challenge to obtaining good quality images.[95a] 
However, as the alveolar space, alveolar septa, and capillary blood are in dynamic exchange, 
it is possible to use nearly all of the inhaled gas to generate 3D images of dissolved 129Xe in 
a single breath-hold, as demonstrated in a number of studies.[95a, 101]
Another challenge is to distinguish between xenon dissolved in the alveolar septa and that 
dissolved in the blood. Various teams have used the chemical shift and the change in 
resonance frequency to distinguish xenon in these two compartments[99a, 102] as the 
dissolved-phase 129Xe signal splits into two distinct peaks in alveolar septa and blood. These 
methods, known as the Xenon Polarization Transfer Contrast (XTC)[99a, 102b, c] and the 
Model of Xenon Exchange (MOXE),[102a, d, e] have been assessed in healthy volunteers[103] 
and patients with obstructive lung disease,[103a] with promising results.
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Further testing these methods, Kaushik et al.[95a] hypothesized that there will be a reduction 
in 129Xe signal intensity in the hemoglobin: alveolar septum ratio in patients with idiopathic 
pulmonary fibrosis (IPF), due to the thickening of the alveolar septa in this condition. MR 
spectroscopy was used to demonstrate the change in signal intensity in patients with IPF 
compared to healthy volunteers. The ratio was significantly lower in the IPF group compared 
to the healthy volunteer group, due to a 52% reduction in the hemoglobin signal and a 58% 
increase in the alveolar septa signal. There was a strong correlation between the hemoglobin: 
alveolar septum ratio and TLco. Therefore, this technique appears to provide a non-invasive 
measure of diffusion limitation and gas transfer impairment.
These findings suggest that 129Xe-MRI has the potential to detect subtle lung function 
deterioration before irreversible structural changes become apparent, providing clinicians 
with the chance to offer therapy (when available), at an earlier stage in order to reverse, halt, 
or delay disease progression.
3.8. Neuroimaging
129Xe-MR brain imaging is emerging as a distinct possibility. Just as xenon can be used as a 
gas exchange probe due to its ability to dissolve across the alveolar-capillary barrier, it can 
also be used as a cerebral blood flow (CBF) probe, as it can cross the blood-brain barrier and 
accumulate in the brain.[104] First used in its non-polarized form for CBF measurement 
using CT in 1982,[105] Swanson et al.[106] were the first group to publish data on brain MR 
imaging using HP 129Xe as an inhaled neuroimaging contrast agent, albeit in rats. Animal 
studies have continued over the past two decades, using HP 129Xe as both an 
inhalational[107] and injectable contrast agent.[108]
Diseased states have also been imaged in the rat model. Xenon signal in the brain is 
proportional to CBF, hence a decrease in the signal is expected to occur in areas of 
decreased CBF, such as those expected in ischemic stroke. Working on this principle, Zhou 
et al.[109] created a rat model of cerebral ischemia by using an intraluminal suture to occlude 
the middle cerebral artery, and demonstrated 129Xe-MRI is able to detect the hypo-perfused 
area of focal cerebral ischemia, which was also confirmed on biopsy. Mazzanti et al.[110] 
further demonstrated the capacity of 129Xe-MRI for functional neuroimaging by inducing 
pain in the rat’s forepaw, and obtaining 129Xe-MR images, which showed 13–28% increase 
in signal compared to the pre-stimulus images; these regions of increased signal 
corresponded to areas previously demonstrated by conventional functional MRI (f-MRI) as 
being activated by a forepaw pain stimulus.
It remains to be seen whether 129Xe-MR neuro-imaging is feasible in humans and of value 
but developmental work is on-going.
3.9. Conclusion
Biomarkers of disease can be classified into diagnostic, prognostic, and theranostic. The 
ideal biomarker encompasses all groups, and 129Xe-MRI has the potential to provide 
diagnostic, prognostic and theranostic biomarkers.
Barskiy et al. Page 10
Chemistry. Author manuscript; available in PMC 2018 January 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
4. Brown-Fat MRI using Dissolved Hyperpolarized 129Xe
For biological MR applications, one of the most interesting properties of HP xenon is its 
high tissue solubility and its chemical shift sensitivity to its molecular environment. 
However, MR imaging and spectroscopy applications of dissolved-phase HP xenon have 
been limited to brain and lung tissues (as described in the sections above), as the 
concentration of dissolved-phase xenon in other tissues is rarely high enough to yield good 
signal after the typical single breath-hold protocol used for human studies. Neglecting 
nuclear spin relaxation and magnetization loss due to NMR pulsing, the time dependence of 
xenon concentration in tissues Ci(t) is well described by the Kety-Schmidt equation:[111]
where λi, is the xenon partition coefficient between tissue and blood, Ca is the arterial 
concentration of the inert gas, and Fi. is the blood flow to the tissue of interest. For most 
tissues, λi, which determines both the maximum concentration achievable in a given tissue 
and the time it takes to achieve maximum concentration, is close to unity.[112] However, Fi, 
which also determines wash-in rate, varies widely. For example, blood flow to the brain is 
very high (~0.5 L/min/kg) and the maximum xenon concentration in this tissue can be 
reached after a few seconds from the beginning of gas inhalation. On the other hand, while 
the solubility of xenon in fatty tissues is almost 20 times higher than in blood, because of the 
low tissue-perfusion (~0.01 L/min/kg), saturation can only be reached after several minutes. 
For HP 129Xe gas, this is a clear limitation, as gas depolarization would limit the amount of 
detectable signal even under continuous HP xenon inhalation.
It was recently shown that the intensity of the xenon dissolved-phase signal could reach 
much higher levels than in the brain in a tissue called Brown Adipose Tissue (BAT).[113] 
Brown adipose tissue is a fatty tissue found in most mammals, including humans, and its 
primary function is to generate heat through a process called non-shivering 
thermogenesis.[114] During stimulation of non-shivering thermogenesis in this tissue, 
intracellular triglyceride oxidation is decoupled from ATP production so that triglycerides 
are mainly burned to produce heat. To support this metabolic activity, BAT is richly 
vascularized. During non–shivering thermogenesis, tissue perfusion increases by several fold 
as blood flow is needed to support the tissue’s oxygen demand and to quickly dissipate the 
heat produced.
Aside from its thermoregulatory function, BAT has recently gained a great deal of interest 
because of its presumed role in the regulation of body weight and blood glucose level. For 
example, a series of studies in rodents have clearly shown that BAT function can directly 
regulate body weight and improve insulin sensitivity.[115] However, the detection of this 
tissue still remains a challenge, especially in humans,[116] where it is sparsely distributed 
and not easy to detect by standard MR techniques. In the paper by Branca et al.,[23] a strong 
enhancement of the intensity of the xenon-dissolved phase signal was reported in mice 
inhaling HP 129Xe right after stimulation of non-shivering thermogenic activity in BAT, an 
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effect which was ascribed to the strong enhancement in blood flow to BAT.[117] Blood flow 
to this tissue during stimulation can reach values as high as 5 L/min/kg,[117] considerably 
reducing xenon wash-in rate and allowing it to reach an in-tissue concentration of 10s of 
mM. Since the increase in blood flow is specific to brown fat cells, background free maps of 
this tissue could be generated.
More interestingly, it was also shown that xenon chemical shift information can provide a 
measure of the relative tissue hydration and tissue temperature. Specifically, two major 
peaks were observed in these studies. One signal, at ~197 ppm, corresponding to xenon 
dissolved in cell cytoplasm/blood, and one signal corresponding to xenon dissolved in the 
lipid droplets of the tissue (~190 ppm), and these signals are challenging to separate in 
mice). The lipid-dissolved peak was shown to have a temperature-sensitive chemical shift 
(−0.2 ppm/°C), which enabled direct measurement of the increase in tissue temperature 
(Figure 5) during non-shivering thermogenesis.[23] In addition, during non-shivering 
thermogenesis, a relative decrease of the lipid-dissolved phase peak was observed with 
respect to the cytoplasm/blood peak, yielding direct evidence of this tissue’s oxidative 
metabolism of internal triglycerides.
More recently, the feasibility of BAT detection in humans during a single breath hold of HP 
xenon was demonstrated, with validation by FDG-PET.[118] As in mice, a strong increase in 
the lipid dissolved xenon signal was seen in the same glucose-avid area of the 
supraclavicular fat depot. More interestingly, xenon spectra showed, in addition to the lipid-
dissolved phase peak, a nearby peak around 200 ppm that was attributed to xenon dissolved 
in red blood cells (RBCs), a signal that provided direct evidence of the strong increase in 
tissue blood flow as the main drive for the increase in xenon tissue uptake.
By being a highly vascularized fatty tissue, BAT is clearly an easy target for the lipophilic 
xenon. In this case, HP 129Xe gas MRI is a “one-stop shop” for human BAT studies as it is 
capable of providing both morphological and functional information.
5. 129Xe Cages and Hyper-CEST MRI
5.1. Bound xenon and molecular hosts
In addition to the NMR study of HP Xe in the gas phase and the studies of tissue-dissolved 
Xe as described above, the affinity of xenon to reside in hydrophobic pockets enables 
additional insights, This phenomenon made xenon a tool for exploring binding sites on 
protein surfaces[2c] with some effort being put on spin polarization transfer to nuclei in 
nearby residues that form the catalytic site of enzymes. Hence, detection of proton signals 
with and without adding HP nuclei could identify the pocket-related residues.[112] Xe NMR 
spectra themselves can also show signals indicative of bound atoms. Such a population could 
either cause a shift of the dissolution peak or a distinct signal given the exchange rate would 
fall into the right regime.[113] An example are red blood cells[114] where the signal of 
“bound” Xe is ascribed to the interaction with hemoglobin.[119] Several experiments first 
used lyophilized protein powder samples, e.g. of lipoxygenases.[120] NMR of dissolved Xe 
has been applied to identify binding pockets of lipid transfer protein,[121] and for observation 
of conformational changes in maltose binding protein,[122] and chemotaxis Y protein.[123] 
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Besides specific site affinity for native structures, protein engineering also allowed for the 
design of conformation-sensitive binding pockets as demonstrated with the ribose binding 
protein.[124]
The binding of Xe to synthetic hosts where the cavity has a simpler design than in proteins 
can be even more pronounced. α-cyclodextrin[125] still comes with fast exchange but 
cucurbit[n]urils[126] (CBn, n = 5,6) show distinct peaks for bound Xe as well as 
cryptophanes, a family of molecular cages with some members that show rather high Xe 
affinity (K > 103 M−1).[127] It has been shown that different members of this group show 
distinct signals of bound xenon (Figure 6a). In particular cryptophane-A, CrA, is often used 
for conferring a distinct chemical shift to bound Xe ca. 130 ppm upfield from the signal of 
free Xe in aqueous solution.
5.2. Xenon biosensor concept
These molecular cages triggered the field of Xe biosensors where CrA is used as the NMR-
active reporter being tethered to a binding unit to reveal the presence of a certain analyte 
(Figure 6b). The first implementation was shown with the biotin-avidin system.[128] This 
original publication also introduced the multiplexing option that this concept offers. This 
feature is inherent to the different cage types (like in Figure 6a), but also small chemical 
modifications on the cage, e.g. deuteration,[128b] already provide a host-guest system with a 
different resonance frequency. Thus the combination of different hosts with different 
targeting units would allow for detecting multiple analytes simultaneously.
The sensing capability initially relied on a change in chemical shift and direct detection of 
the bound Xe signal–a concept that was later partially revised due to anticipated loss of 
spectral resolution in cells and live animals. Optimization for this concept included first and 
foremost increasing the Xe affinity and maximizing the detected chemical shifts. It is 
obvious that the cage size impacts the binding constant as illustrated in a comparative 
review,[129] but substitutions on CrA and cryptophane-111 can also increase the affinity.[130] 
Understanding the details behind the complexation of Xe revealed induced fit properties[131] 
and displacement of water[132] as contributing forces. The linker length between cage and 
targeting unit is a critical parameter for enabling the right balance between sufficient 
mobility required for narrow resonances and desired surface contact with the target to shift 
the signal.[133] Another relevant aspect of cryptophane-based sensors is the poor water 
solubility of the host. While many cages were first characterized in organic solvents, various 
synthesis studies succeeded to improve solubility.[130c, 132, 134]
5.3. Hyper-CEST signal amplification
The focus on the binding properties somewhat shifted with the advent of MR imaging 
protocols for such sensors. The low concentration of caged atoms (typically < 10−5 M) 
requires extensive signal averaging for conventional detection. Initial imaging applications 
were slow and limited to selected spatial dimensions.[135] To improve this situation, the 
chemical exchange of Xe became an important parameter. One method for enhanced 
sensitivity in spectroscopy applications uses selective read-out of the caged Xe signal while 
the pool of dissolved Xe serves as a polarization reservoir.[136] This principle was also used 
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in imaging[137] but has its limitations due to the timing that comes with frequency selective 
excitation pulses with defined flip angles.
However, inverting the roles of the participating pools, i.e. manipulating the dilute pool and 
detecting the abundant solution pool, enables significant signal enhancements. The method 
with selectively saturating the magnetization from the dilute pool (either through cw 
irradiation, or by using a train of shaped excitation pulses) and observing the signal decrease 
of the other pool (Figure 6c) is called chemical exchange saturation transfer (CEST), first 
introduced by Balaban and co-workers.[138] Combining CEST with HP nuclei was first 
demonstrated by the Pines lab for an imaging application and coined Hyper-CEST.[139] With 
Hyper-CEST, host concentrations as low as ~10−8 M become accessible—even for 
imaging.[140] The effect strongly depends on the exchange rate and therefore it can also 
sense system parameters like ambient temperature.[141] The spectral dimension can be 
recovered by performing a series of experiments in which the saturation pulse is swept over 
a certain frequency range (Figure 6d), thus providing another method to sense parameters 
that influence the chemical shift.[142] It also preserves the multiplexing option mentioned 
early on.
5.4. Xe Biosensor Applications in Cell Biology
The improved detection limits for imaging made it possible to address problems under more 
biologically realistic conditions. To date, cryptophane-based sensors that use specific 
binding to the target have been implemented for sensing the enzyme MMP7,[143] 
nucleotides,[144] human carbonic anhydrase,[145] MHC class II,[146] zinc ions,[147] the 
glycoprotein CD14[148] and the receptors for integrin,[149] transferrin,[150] EGF,[151] and 
folate.[152] An indirect binding approach was pursued through in situ click chemistry with 
metabolically labeled cell surface glycans.[153] Conformational changes of the sensor 
induced by changes in pH represent an approach for stimulus-induced binding.[154]
As part of these studies, cell uptake and toxicity evaluations set the bar for target 
concentrations of functionalized hosts.[149, 155] Xe itself passes the cell membrane[150] and 
does not require further attention to reach intracellular targets. Cell-penetrating peptides 
proved to be a valuable measure for achieving micromolar intracellular concentrations. 
However, they are not an absolute requirement since the hydrophobic character of CrA can 
mediate membrane-association and therefore enables certain types of cellular labeling.[156] 
Sensors with highly specific binding motifs (e.g., antibodies[148, 151] or bioorthogonal 
reaction partners[153]) only require sample-averaged concentrations of 10−8 M for MRI.
Critically, the membrane affinity of CrA can be clearly identified by a ca. 10 ppm downfield 
shift for Xe in membrane-associated CrA.[157] This property proved primarily useful to 
identify cell-associated cages in the first live-cell experiments.[150, 156a] A closer look in 
combination with FRET data revealed partitioning coefficients on the order 102–103 for 
different membrane compositions.[158] This work also initiated a new class of Hyper-CEST 
experiments for investigating membrane fluidity and integrity: Due to the accelerated 
exchange, Xe signals from membrane-embedded cages do only differ marginally in 
chemical shift. However, build-up of the CEST effect can be very different depending on 
membrane fluidity. Comparative studies are possible when irradiating a pool of caged Xe at 
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fixed saturation power and frequency but increasing saturation time. Evaluating the 
(multi-)exponential depolarization with an inverse Laplace transformation yields 
characteristic time constants for different environments.[159] The method called DeLTA 
(depolarization Laplace transform analysis) can also be used to discriminate cholesterol 
content and the onset of lipid domain fluctuations.[160]
5.5. Host Optimization
In order to explore a large chemical shift range of different sensors, the impact of metal ion 
chelation in close proximity to the cage provides a means to diversify signals.[161] Along 
this line, attached Gd-chelates can serve as relaxation switches for 129Xe which are 
detachable through chemical reactions.[162] Regarding Hyper-CEST detection, improved 
efficiency depends on the exchange properties, which are sub-optimal for CrA. Faster 
exchanging hosts such as CB6[163] and CB7[164] are currently under investigation. Their 
binding properties for competitive guests must be taken into account but this versatile 
binding phenomenon on the other hand enables the option to implement detection of other 
guests via displacements approaches. An example is the mapping of lysine decarboxylase 
LDC activity where the enzymatic product cadaverine quenches the Hyper-CEST effect.[164] 
Related to this is an implementation of a sensor relay in which the cavity becomes accessible 
for Xe as soon as another host recruits the original guest from the CB6 cavity.[165] The 
macrocyclic host also allows construction of rotaxanes that keep the cavity blocked. 
Cleaving one of the rotaxane stoppers releases the thread and makes CB6 available for 
Hyper-CEST detection.[166] This recent design could serve as a development platform for 
various sensors based on cleavage reactions.
Many dilute targets will only be accessible with an increased number of CEST sites per 
targeting unit. For this purpose, multivalent carriers with 102 – 103 Xe hosts will be the right 
tool. They have been implemented with scaffolds such as bacterial phages,[151, 167] viral 
capsids,[168] and liposomes.[169] Alternatively, nano-compartments absorbing small amounts 
of Xe gas can be used, one example being PFOB nanodroplets.[170] The first imaging 
experiments with the latter substance also included the first multi-channel read-out of 
different host classes.[156b] Similar host compartments such as gas vesicles[171] and bacterial 
spores[172] will be discussed separately in the following section.
5.6. Hyper CEST analysis and data encoding
Stable and reproducible HP Xe delivery with shot-to-shot noise < 1% achieved through 
temperature stabilization of the pumping cell[173] allows one to further investigate the 
predicted line-shape for Hyper-CEST spectra, i.e. an exponential Lorentzian.[174] Linked to 
this theoretical description is an approximation for the Bloch-McConnell equations that 
allows prediction of the build-up of the Hyper-CEST effect and quantification of the 
exchange parameters.[175] Comparison of hosts can then be done by using the gas turnover 
rate.[163b] The exchange dynamics also set the boundary conditions for maximum signal 
contrast and an orientation for optimum saturation parameters.[176] It is important to achieve 
the saturation transfer before the intrinsic T1 relaxation dominates with its signal loss.
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For imaging, the CEST information needs to be encoded as fast as possible. Fast imaging 
sequences can replace the original point-wise encoding[139] given sufficient magnetization. 
Echo planar imaging (EPI) allows sub-second imaging,[140] with particular application to 
hyperpolarized imaging using variable flip-angle excitation in an approach called 
smashCEST. These rapid imaging approaches enable time-resolved studies, including the 
monitoring of diffusion.[140] Image quality can be improved by exploiting redundancies in 
the spectral domain[177] during encoding and post-processing. Spin-echo encoding is an 
alternative for cases where T2* relaxation makes EPI encoding impractical.[156a]
Interest in Hyper-CEST agents has led to the development of fast strategies for gradient-
encoded CEST spectra at up to 40-fold reduced scan times.[178]
6. Genetically Encodable Hyperpolarized 129Xe MRI Contrast Agents
Genetically encoded MRI reporters are contrast agents that can be produced by genetically 
transfected cells to enable the tracking of cells, imaging of gene expression, or sensing of 
specific aspects of cellular function. Among the advantages of these reporters over synthetic 
agents are that they can be introduced into cells using established gene-delivery techniques, 
avoid dilution with cell division, and that a large genetic engineering toolbox can be used to 
modify and optimize protein-based reporter performance. Furthermore, these agents leverage 
the recent boom in molecular biology methods to manipulate and deliver genetic materials to 
animals, such as transgenic mouse lines, viral therapy, RNA interference, and genome 
editing.
Most existing genetic reporters have been designed for 1H MRI. Examples include enzymes 
or transporters that can act on synthetic contrast agents,[179] proteins that naturally contain 
paramagnetic metals, including ferritin,[180] MagA,[181] MntR,[182] tyrosinase,[183] and 
cytochrome P450,[184] and diamagnetic CEST agents such as lysine rich-protein,[185] human 
protamine sulfate[186] and proteins that alter water diffusivity in tissue.[187] Comparatively 
fewer contrast agents have been designed for heteronuclear MRI, all of them based on 
enzymatic or transporter interactions with 19F compounds,[188] HP 13C 
compounds,[188c, 189] or 31P substrates.[190] A major challenge of all of these agents is their 
relatively low molecular sensitivity, typically of the micromolar or higher order, which limits 
their range of in vivo applications. Several excellent reviews have been written on these 
classes of MRI reporters.[191]
Given the sensitivity gains of HP 129Xe MRI and in particular HyperCEST, there is a strong 
incentive to develop genetically encoded MRI reporters acting on xenon. However, this 
prospect is challenging due to the weak interaction of xenon with most proteins. Xenon-
binding proteins have been identified through X-ray crystallography, wherein xenon is used 
as a heavy atom marker to aide in structure elucidation,[192] and NMR, wherein the 129Xe 
chemical shift can probe proteins’ confirmation and ligand binding.[193] Examples of 
proteins shown to interact with xenon include myoglobin[194] and hemoglobin, maltose 
binding protein[113] and lysozyme[120]. These interactions are attributed primarily to 
enthalpic Debye and London interactions, with a smaller entropic contribution from xenon 
dehydration as it enters a hydrophobic cavity.[193b] Unfortunately, although protein binding 
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was shown to shift the resonance frequency of xenon by several ppm/mM, these proteins are 
not suitable as 129Xe-MRI contrast agents because their xenon affinities (~10 mM) would 
require unrealistic quantities of protein to be present to achieve significant direct contrast, 
while their xenon exchange rates (dissociation constant ~ 105 s−1)[194] are too fast compared 
to the induced xenon chemical shift (Δω ~ 103 – 104 s−1) to enable efficient HyperCEST 
contrast.
A major advance in the development of genetically encoded reporters for Xe-MRI was made 
in 2014, when Shapiro et al. reported that an unusual class of gas-filled protein 
nanostructures called gas vesicles (GVs) could produce efficient HyperCEST contrast at 
picomolar concentrations.[25] GVs, which evolved in photosynthetic microbes as a means to 
regulate buoyancy, comprise hollow gas compartments at hundreds of nm in size and possess 
a 2 nm protein shell that is permeable to gas but excludes liquid water[195] (Figure 7a,b). 
Shapiro et al. showed that GVs can interact with xenon to produce HyperCEST contrast with 
peak saturation approximately 175 ppm upfield from dissolved 129Xe (Figure 7c,d). The 
large chemical shift separation enables the contrast to be extremely efficient, with a GV 
detection limit in the picomolar range (Figure 7e), orders of magnitude lower than 
comparable proton contrast agents. Furthermore, GVs formed by different species of 
bacteria and archaea, in which these nanostructrues differ in size and shape, produce 
HyeprCEST saturation at different chemical shifts, thereby enabling multiplexed imaging. In 
their initial study, Shapiro et al. provided proofs of concept for GVs as antibody-
functionalized markers of cancer cells and as reporters of gene expression in E. coli. In 
addition to GVs, other biological structures may be able to serve as HyperCEST agents. For 
example, bacterial spores, a dormant cellular state comprising a multi-layered structure of ~ 
1.5 μm size, were recently demonstrated for HyperCEST at a chemical shift 4.5 ppm 
downfield from aqueous xenon.[172]
The discovery of GVs as highly efficient biomolecular reporters for HyperCEST leads to 
several interesting questions and possibilities that merit further investigation. If we assume 
that an optimal CEST saturation can always be achieved with sufficient RF power and that 
the relaxation of 129Xe is minimal during CEST experiment, then HyperCEST sensitivity is 
determined by (a) the chemical shift difference and (b) the exchange rate between the 
contrast-agent-bound and the dissolved 129Xe spins.[196] Regarding the chemical shift, each 
GV has a several-attoliter gas chamber containing thousands of gas atoms or molecules, 
where 129Xe atoms presumably experience an environment similar to gas phase, and 
consequently compared to the synthetic contrast agents, GV-associated 129Xe chemical shift 
is usually closer to that of the gas phase. Intriguingly, the specific value of chemical shift 
appears to be genetically determined.[25] It will be interesting to study how this chemical 
shift relates to other genetically encoded GV properties, including their size, shape and 
aggregation state, and the extent to which these properties can be tuned at the genetic level. 
In terms of the exchange rate, when the Z spectra (i.e. the frequency-dependent saturation 
effects are visualized similar to conventional magnetization transfer spectra by plotting the 
water saturation (Ssat) normalized by the signal without saturation (S0) as a function of 
saturation frequency) acquired with intact and collapsed GV are compared with those 
acquired with synthetic agents, both the GV-bound and the dissolved 129Xe peaks appear to 
be broader, suggesting the exchange rate is in the intermediate regime. It will be interesting 
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to define quantitatively the optimal RF saturation parameters for the specific exchange rate 
of GVs. On the molecular level, though the atomic-level structure of the GV wall has not 
been solved, some hypotheses have been proposed regarding the channels on the protein 
shell that allow gas exchange in and out of the nanostructure[195b]; it is possible that 
variation (natural or engineered) in the amino acid sequence of GV proteins could alter the 
permeability of these putative pores. Taken together, GVs present a wide dynamic range 
for 129Xe chemical shifts and exchange rates, and these two properties are likely amenable 
to protein engineering for new and optimized forms of 129Xe HyperCEST.
It is also worth noting that in addition to serving as HyperCEST reporters, GVs produce 
contrast in at least two complementary imaging modalities. First, they are the first 
genetically encodable imaging agents for ultrasound,[197] where their low density and high 
elasticity relative to surrounding media allows them to scatter sound waves. Secondly, their 
gas-filled interior, which has a different magnetic susceptibility from surrounding solution, 
allows GVs to produce 1H MRI contrast in susceptibility-weighted imaging.[198]
The list of genetically encoded 129Xe-based HyperCEST reporters has been recently 
expanded to include β-Lactamase by Dmochowski and co-workers.[199] As a small protein 
encoded by a single gene, this reporter may be easier to use in some settings than GVs, 
albeit with somewhat lower molecular sensitivity.
7. Parahydrogen
Hydrogen exists in two nuclear spin isomers denoted as ortho- and para- corresponding to 
the nuclear triplet and singlet states, respectively, where parahydrogen corresponds to the 
states with an even rotational quantum number J whereas orthohydrogen corresponds to odd 
values of J. The ratio of the two isomers is determined by the Boltzmann thermal 
equilibrium for the given rotational state J, Figure 8.[200] For a more detailed discussion of 
the physics and applications of parahydrogen beyond the scope of this mini-review, we refer 
the interested reader to the 1935 book by Farkas on hydrogen[200] or various excellent 
discussions.[201]
Importantly, conversion between the two states occurs extremely slowly due to the transition 
being forbidden by the selection rules of quantum mechanics, leaving only statistically 
unlikely naturally occurring processes of sufficient energy (radiation, molecular collisions, 
etc.) to foment interconversion. Therefore, after its production (and provided lack of 
exposure to sources of paramagnetic impurities in the storage vessel), parahydrogen may be 
stored for long periods before use, as the relaxation rate of the parahydrogen back to room-
temperature equilibrium can be on the order of months.[202] Production rates are 
significantly faster, however, since as discovered in 1929 by Bonhoeffer and Harteck, the use 
of paramagnetic catalysts (i.e. activated charcoal, nickel, hydrated iron (III) oxide) promotes 
establishment of Boltzmann thermodynamic equilibrium between ortho-H2/para-H2 states 
for a given temperature at greatly accelerated rates. In practice, normal hydrogen gas (i.e. 
equilibrium ratio at room temperature) consisting of 75% ortho- and 25% para- isomers is 
passed through a paramagnetic catalyst filled chamber at cryogenic temperatures, where the 
equilibration to the isomer ratio governed by the Boltzmann distribution occurs. For 
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example, a parahydrogen generator based on 77 K (obtained conveniently by a liquid-N2 
bath) yields ~50% parahydrogen mixture, whereas the designs based on cryo-chillers (e.g. 
T≤20 K) yield ≥99% parahydrogen (Figure 8).
8. Fundamentals of Parahydrogen-Induced Polarization (PHIP)
In 1986 Russ Bowers and Daniel Weitekamp proposed a method for achieving very high 
nuclear polarizations using parahydrogen.[7a] Dubbed PASADENA (Parahydrogen And 
Synthesis Allow Dramatically Enhanced Nuclear Alignment), the effect predicted strongly 
enhanced 1H NMR signals for hydrogenation reaction products when unsaturated molecular 
precursors are hydrogenated with parahydrogen. Later they demonstrated the effect 
experimentally by hydrogenating acrylonitrile with parahydrogen using Wilkinson’s 
catalyst.[7b] Anti-phase 1H NMR multiplets were demonstrated for the reaction product, 
propionitrile, and for dihydride rhodium complex – the reaction intermediate. It was later 
realized that experimental demonstrations of the PASADENA effect had already been 
published,[203] but had been misinterpreted as chemically-induced dynamic nuclear 
polarization.[7c] PASADENA and (the later discovered) ALTADENA[204] are collectively 
dubbed as the process denoted as parahydrogen-induced polarization (PHIP).[11c] This 
seminal discovery of Bowers and Weitekamp opened up a new strategy for hyperpolarization 
of various compounds, and currently PHIP and its recent modification, SABRE (Signal 
Amplification By Reversible Exchange),[8] are used to obtain HP molecules 
with 1H,[11c, 201b] 13C,[12] 15N,[13d] 19F,[14] and 31P[15] nuclei in a hyperpolarized state.
Detailed explanation of the spin dynamics and chemical kinetics behind PHIP can be found 
in several comprehensive reviews.[11c, 201, 205] Here we briefly discuss the main principles of 
PHIP to qualitatively describe the phenomena discussed below. As an example, we take the 
simplest two-spin system. The two-spin system of the hydrogen molecule gives rise to four 
nuclear spin energy levels. As described above, three of these energy levels correspond to 
orthohydrogen, the state with total nuclear spin 1 (triplet state), whereas the remaining 
fourth energy level corresponds to parahydrogen (singlet state), the state with zero total 
nuclear spin. Transitions between singlet and triplet spin states are forbidden by 
symmetry;[7a] and the spin 0 parahydrogen is NMR-silent.
Bowers and Weitekamp’s idea was to break the magnetic equivalence of two hydrogen 
nuclei by using parahydrogen in a hydrogenation reaction (Figure 9a), thus, making 
prohibited transitions allowed. Indeed, upon incorporation of a parahydrogen molecule into 
an asymmetric molecular precursor, the symmetry of the para-H2 molecule becomes broken. 
This situation strongly depends on the magnetic field at which the hydrogenation reaction 
takes place. If hydrogenation is performed at high magnetic field B0 (i.e., wherein the 
chemical shift difference between the two para-H2-nascent protons,Δδ, is much greater than 
the spin-spin coupling J between them (γΔδB0 > 2π )), then the population of the singlet 
spin state (αβ – βα ) of para-H2 is transferred to the population of spin states αβ and βα of 
the formed weakly coupled AX spin system (PASADENA effect, Figure 9b).[7b] The NMR 
spectrum of the AX system populated in this way will contain four peaks grouped in two 
antiphase multiplets (Figure 9b). Two lines (positive-negative or negative-positive, 
depending on the sign of spin-spin coupling constant J) in each multiplet are separated by J 
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Hz in the case of isotropic liquids and/or gases.[206] PASADENA-hyperpolarized organic 
molecules are typically manifested in 1H NMR spectra as positive-negative multiplets, 
whereas multiplets for hydride intermediates are negative-positive, since through-electron 
mediated J couplings are negative for metal hydrides.[207] Interestingly, signal intensity of 
PASADENA spectrum is maximized when 45° (instead of 90°) pulse is applied for signal 
acquisition, which may be shown using density operator description of the PHIP 
process.[205]
On the other hand, if the hydrogenation reaction takes place at low magnetic field (such that 
γΔδB0 ≤ 2π; e.g., at the Earth’s magnetic field), and afterwards the hydrogenation product 
is adiabatically transferred to a high magnetic field, then there is a single state that is 
overpopulated, i.e. αβ or βα —depending on the sign of the J-coupling constant between the 
nuclei (ALTADENA effect, Figure 9c).[204] In this case spectral pattern will consist of four 
lines grouped in two “integral multiplets” simply corresponding to one spin “up” and second 
spin “down” state (Figure 9c).
In order to be able to observe PHIP for the molecule of interest several key conditions must 
be fulfilled:[11c]
1. The addition of parahydrogen to the unsaturated precursor should occur in a 
pairwise manner. Pairwise addition implies that two hydrogen atoms from the 
same H2 molecule are included in the product molecule together as a pair, thus 
preserving spin correlation between the two proton spins.
2. The characteristic nuclear spin relaxation time for para-H2-nascent protons 
should be longer than the time needed to complete the pairwise hydrogenation 
process.
3. The magnetic equivalence of the two correlated nuclear spins should be broken 
during the hydrogenation[208] or in the product of the hydrogenation reaction.[7b]
If all of the above-mentioned conditions are fulfilled, the product of the hydrogenation 
reaction will possess a non-equilibrium population distribution of its nuclear spin energy 
levels owing to either the PASADENA or ALTADENA process.
One should note that the final polarization of the hydrogenation reaction product does not 
depend on the magnetic field strength, and the polarization obtained by PHIP in principle 
can reach 100% (neglecting spin relaxation and/or decoherence).[7a, 205] In principle, 
enhancement of the NMR signal can be as high as several thousand-fold above ordinary 
thermal signals from high-field NMR spectrometers and even a million-fold at low magnetic 
fields.
Since the hydrogenation reaction does not proceed spontaneously, the key component of the 
system is a catalyst (Figure 9a), which (i) enables hydrogenation reaction, and (ii) provides 
efficient pairwise addition of molecular hydrogen to the substrate. All hydrogenation 
catalysts can be classified as homogeneous or heterogeneous depending on their phase 
relative to the substrate. Homogeneous catalysts are present in the same phase as the to-be-
hydrogenated substrate (typically, liquid phase), whereas heterogeneous catalysts are present 
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in a phase different from the phase of the substrate (usually, a solid catalyst and a gaseous or 
liquid substrate). Since the first demonstration by Bowers and Weitekamp,[7b] homogeneous 
catalysts have become widely used to produce PHIP, which is reasonable: it is known that 
hydrogenation mechanisms using metal complexes can usually provide an efficient route for 
pairwise hydrogen addition. For a long time, the feasibility of using heterogeneous catalysts 
for production of PHIP was rejected based on the known mechanism of heterogeneous 
hydrogenation, i.e. the Horiuti-Polanyi mechanism. According to Horiuti and Polanyi,[209] 
hydrogen molecules dissociate on metals (typically used as heterogeneous hydrogenation 
catalysts) and form a pool of randomly moving free hydrogen atoms, thus not fulfilling 
condition 1 (pairwise addition) above.[210] Nevertheless, it was shown that various classes of 
heterogeneous catalysts, i.e. immobilized metal complexes,[9a] supported metal 
nanoparticles,[28b] etc., can enable the PHIP effect. In the current mini-review both classes 
of catalysts are considered.
9. Gases hyperpolarized via PHIP
As mentioned in the introduction, MRI of gases suffers from poor sensitivity due to their low 
molecular density compounded with the low thermal polarization of their nuclear spins. 
These problems can make it challenging to image gas-filled void spaces due to the very low 
signal-to-noise ratio (SNR) and the usually long signal-averaging times, which can be 
prohibitive for many clinical applications. HP noble gases[211] can be used to address these 
issues. However, the production of HP noble gases is relatively expensive, necessitating 
costly hyperpolarizer equipment. Moreover, imaging of HP noble gases requires a dedicated 
X-band channel (for the heteronucleus of interest) and radio-frequency probe, which are not 
standard features of clinical MRI scanners (although they are becoming increasingly 
prevalent). Therefore, production of non-toxic HP proton-containing gases via PHIP could 
be a promising alternative that avoids the above technical requirements of HP noble gases.
9.1. Production of hyperpolarized gases using PHIP
Historically, experiments with parahydrogen were predominantly conducted in the liquid 
phase, wherein fluids hyperpolarized by PHIP reside in a solution along with a 
homogeneous hydrogenation catalyst.[201b] Heterogeneous catalysts can be used to separate 
the HP product from the catalyst.[29, 212] At the same time, it is also possible to produce 
catalyst-free HP gases by combining the main advantage of homogeneous (high selectivity) 
and heterogeneous catalysis (easiest catalyst separation) by using gas-liquid biphasic 
hydrogenation. Utilization of a homogeneous catalyst dissolved in the liquid phase for 
biphasic hydrogenation of unsaturated gases with para-H2 allows one to produce HP gas that 
is free from contamination by the catalyst. In the demonstration of this approach it was 
shown that the reaction product can return to the gas phase while retaining a significant 
degree of hyperpolarization.[213] This feature significantly extends the range of gases that 
can be hyperpolarized. It was shown that utilization of a simple experimental procedure 
allows one to achieve signal enhancements of 300 for propyne hydrogenation to propylene 
using the bidentate cationic complex [Rh(PPh2-(CH2)4-PPh2)(COD)]BF4.[213] Another 
approach for HP gas production is the use of homogeneous catalysts based on a judicious 
choice of the metal complex (homogeneous hydrogenation catalyst) in which the desired 
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unsaturated substrate is coordinated to the metal center.[214] In that case hydrogenation with 
parahydrogen allows the substrate to leave the metal center and to migrate to a different 
phase with preservation of the spin order of the two nascent protons derived from the para-
H2 molecule. Indeed, it was shown that PHIP-hyperpolarized gas can be obtained in a 
catalysis-free regime using a chemical reaction with molecular addition of parahydrogen to a 
water-soluble Rh(I) complex carrying a payload of a compound with double (C=C) 
bonds.[214] Hydrogenation of the norbornadiene ligand leads to the formation of norbornene, 
which is expelled from the Rh(I) complex to the aqueous phase, but due to its insolubility in 
water HP norbornene quantitatively leaves the solution to the gas phase (Figure 10).[214]
As soon as PHIP was successfully demonstrated in heterogeneous hydrogenations over 
immobilized[9a] and supported metal catalysts,[28b] the production of HP gases over these 
catalysts became an important area of PHIP-related investigations. Many different 
heterogeneous catalysts were used for the production of HP gases in the past eight years, 
with the aim to find the catalyst with the highest level of pairwise hydrogen addition for a 
given substrate.[29, 215] Without doubt the utilization of a solid catalyst allows one to 
produce HP gases in the continuous-flow regime by passing a mixture of an unsaturated 
substrate with para-H2 through the catalyst layer. In this approach, hydrogenation occurs at 
the Earth’s magnetic field and corresponds to the ALTADENA[204] type of PHIP 
experiment. Note that the nature of the heterogeneous solid catalyst can have a significant 
impact on the polarization level, and titania-supported metal catalysts were shown to exhibit 
larger PHIP effects compared to metals on other supports.[216] The polarization level for HP 
gases produced over supported metal catalysts can be several percent,[28b, 217] and it 
increases with the decrease in the size of the supported metal nanoparticles.[218]
9.2. MRI of hyperpolarized hydrocarbon gases
Continuous production of HP gases via heterogeneous hydrogenation paves the way to the 
potential practical applications for imaging of void spaces by MRI. The first experiments 
were related to MRI visualization of HP propane in a NMR tube with a cross-shaped 
partition or with a series of capillaries.[9b] For that work, a mixture of para-H2 and propene 
gas was flowed through a reactor cell with the heterogeneous catalyst (e.g. Rh immobilized 
on titania). After that the product (HP propane gas, Figure 11) was transferred to the NMR 
magnet and the ALTADENA enhancement was evident in the MR images, Figure 12a.
For both model samples, detection of the NMR signal of a thermally polarized gas did not 
produced observable images, whereas the use of PHIP-polarized propane gas allowed one to 
visualize the corresponding structures of the objects used in the experiments.[9b] 
Importantly, the demonstrated 300-fold signal enhancement in the gas-phase MRI is 
sufficient to image gases with a similar spatial resolution as that in corresponding liquid-
phase MRI experiments. The subsequent development of the strategies for 1H MRI 
visualization of both hyperpolarized and thermally polarized propane gas for high-resolution 
MRI applications allowed one to significantly decrease the imaging time. Compared to 
FLASH MRI[219] (Figure 12), the use of UTE MRI[220] decreases the total imaging time 
significantly, down to the regime sufficient for MRI of a patient within a single breath-hold 
in a future clinical translation. It was shown that utilization of UTE MRI makes it possible to 
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obtain 2D images of thermally polarized with ca. 0.9 × 0.9 mm2 spatial resolution in ca. 2 s 
(and potentially with better resolution for HP gases).[221]
Recently, HP propane gas produced by heterogeneous hydrogenation of propene over 
supported metal catalysts was utilized for 3D 1H MRI with micro-scale spatial resolution 
(625×625×625 μm3), large imaging matrix size (128×128×32) and short (17.4 s) image 
acquisition time.[216a]
Utilization of a fully deuterated substrate (propene-d6) in the heterogeneous hydrogenation 
with para-H2 permitted acquisition of a high-resolution 3D MRI image of flowing HP 
propane-d6 gas with 0.5 × 0.5 × 0.5 mm3 spatial and ~18 s temporal resolution (Figure 
13a).[222] It was shown that the signal-to-noise ratio in the 3D images of HP propane-d6 gas 
(Figure 13a) and water (Figure 13b) are similar. This observation confirms that the 
utilization of a gas hyperpolarized by PHIP allows one to obtain MR images with quality 
similar to that obtained with water as the signal source.
Utilization of HP gases produced by PHIP is not limited only to void space imaging. Indeed, 
it was shown that a catalytic reactor positioned inside an NMR magnet can be imaged in situ 
during heterogeneous hydrogenation of propene to propane with parahydrogen.[28a] In situ 
MRI of a catalytic reaction allows one to visualize the regions in the catalyst layer where the 
hydrogenation reaction occurs. Importantly, based on the significant signal enhancement the 
velocity map for HP gas forming in and flowing through the catalyst bed was obtained.[28a]
Given the above results, PHIP is clearly becoming an important technique for signal 
enhancement in both fundamental, basic science and biomedical MRI investigations. 
Moreover, the use of PHIP to produce HP gases can be useful for their potential utilization 
in medical MRI applications.
10. Remote-detection MRI of Hyperpolarized Gases
MRI of gases in small voids, such as in porous media, microreactors, and microfluidic 
devices, suffers from particularly low sensitivity due to an additional exacerbating factor: 
low filling factor in the NMR coil, which may be less than 10−5 in some cases. While HP 
methods partially compensate for the low sensitivity, an additional sensitivity boost provided 
by alternative detection methods may be required. These methods include, for example, 
surface RF microcoils, RF microslots, and remote detection (RD), to name a few.[223]
In RD MRI,[224] encoding of spatial information and signal detection are performed with 
different coils (see Figure 14a). The encoding RF coil is a large coil around the whole 
sample, so that all spins can be excited. Signal detection is performed outside the sample 
with a much smaller and more sensitive RF coil, with an optimized filling factor.[225] The 
technique requires that the encoded spins are transported to the detector before the 
magnetization is fully relaxed, and it inflicts one additional dimension as compared to 
conventional MRI, because it is based on phase encoding only. Nevertheless, it provides a 
substantial sensitivity boost as an ultrasensitive detection solenoid may be hundreds of times 
more sensitive than the encoding coil.[226] Furthermore, the flow delivers spins from the 
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different parts of the sample to the detector at different times, and this inherent time 
dimension can be utilized to produce time-of-flight (TOF) flow images.[227]
10.1. Time-of-flight flow imaging with HP gases
HP Xe is an ideal probe fluid in RD MRI experiments, because the T1 relaxation time 
of 129Xe can be extremely long, allowing correspondingly long transport times from the 
sample to the detector. HP Xe RD MRI has been used for imaging flow through porous 
materials,[224, 228] rocks,[227] microfluidic devices,[226] and wood,[229] as well as for 
quantifying diffusion through membranes.[230] Figure 14b shows a remarkable example of 
3D TOF images of HP Xe flowing through a rock sample. The shortest TOF image (TOF = 
0.27 s) shows spins that were at the top of the encoding region, because they arrived first to 
the detector, and the longest TOF image (TOF = 0.98 s) shows the spins at the sample 
bottom.
Gaseous HP hydrocarbons produced by PHIP have been used in RD MRI experiments as 
well.[231] T1 values for spins of hydrocarbons are typically much shorter (~ 1 s) than that 
of 129Xe, limiting the transport time of fluid from the sample to the detector; however, if the 
sample coil and the detection coil are close enough and the flow rate is sufficiently high, the 
experiments are feasible. Because the gyromagnetic ratio and the natural abundance of 1H is 
much higher than for 129Xe, the sensitivity in PHIP experiments may be significantly higher.
As an example, Figure 15b shows 2D RD MR images of HP propane, which was produced 
by propene hydrogenation with para-H2 over an Rh catalyst, flowing in a microfluidic 
capillary.[231a] Overall, the combined sensitivity gain provided by the RD scheme and PHIP 
was 48,000-fold, and the experiments turned out to be one to two orders of magnitude more 
sensitive than the corresponding RD experiments with HP Xe. Comparison of the TOF 
images of a gas and a liquid (Figures 15b and 15c) nicely depicts different flow behavior of 
these phases; laminar flow of a liquid translates the encoded liquid molecules over a large 
distance (Figure 15c), whereas for a gas the three orders of magnitude faster diffusion causes 
efficient mixing of the flow lamellas, leading to a significantly less dispersed, plug-like flow 
behavior (Figure 15b).[231a, b]
Experiments with model microfluidic chips have supported the viability of the RD-PHIP 
approach for visualization of complex microfluidic geometries and flow quantification, 
Figure 16.[231a] Moreover, these experiments exposed the manufacturing imperfections of 
the chips. The gas flow in different channels varied in an irregular manner, and the signal 
amplitude profiles revealed an inhomogeneous distribution of the gas, implying that the 
channel depth varied from one channel to another.
10.2. Microfluidic reactor imaging
The natural ability of para-H2 to participate in many important chemical reactions, including 
those performed with the use of microfluidic devices, opens an avenue for scientifically and 
technologically fascinating studies using HP gases. Combined RD MRI and PHIP 
methodologies in such studies was exemplified by the demonstration of catalytic reaction 
imaging of microscale catalyst layers.[231c] Tiny layers of heterogeneous Rh catalyst packed 
in thin capillaries (150–800 μm in diameter) served as model microfluidic reactors. It was 
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shown that the RD-PHIP methodology can be used for visualization of mass transport and 
progress of gas-phase propene hydrogenation reaction inside the reactors.
The white dashed rectangles in Figure 17 highlight the locations of the catalyst layers. The 
accumulation of produced HP propane with the distance that gas mixture travels inside the 
catalyst layer is visualized by the increased signal amplitude in the lower part of the reactor. 
It was shown that under the given conditions (relatively short travel times), the signal decay 
due to nuclear spin relaxation was quite insignificant, and the amplitude of the HP propane 
signal was directly proportional to reaction yield, allowing the determination of the rate of 
propene hydrogenation.
In addition, the experiments enabled the observation of gas adsorption effects in the 
microfluidic reactors during their in situ operation, and an elegant approach for quantifying 
the amount of absorbed gas using RD NMR was proposed. The authors also introduced the 
concept of a microfluidic nuclear polarizer based on their findings about PHIP produced in 
the microscale heterogeneous catalytic hydrogenation.
Further efforts were directed to the development of the concept by employing micro-
engineering technologies to produce micro-structured lab-on-a-chip reactors with the 
catalyst (sputtered Pt) deposited on the inner surface of the channels.[232] It was found that 
these reactors did not provide PHIP. However, these studies provided a platform for further 
development of RD NMR for future HP applications, e.g., by using Hadamard encoding to 
achieve a better chemical resolution.[232b]
10.3. Outcome and perspectives
The current advances in RD MRI with HP gases already offer many interesting applications 
as highlighted above. The major issues concerning the methodology are related to the 
availability of HP gases and the lifetime of hyperpolarization. HP 129Xe is typically more 
expensive than the 1H HP hydrocarbon gases produced using PHIP. On the other hand, the 
nuclear spin relaxation causes more severe problems in the case of HP hydrocarbons. Recent 
developments in the field of long-lived nuclear spin states,[233] however, may alleviate the 
latter problem. For instance, it has been shown that a long-lived HP state in ethylene gas can 
survive for ca. 15 min.[234] The further RD NMR development could concern utilization of 
such extremely long-lived HP. In addition, the progress achieved in the field of single-scan 
ultra-fast NMR techniques[235] also offers new capabilities, which earlier were considered 
incompatible with NMR hyperpolarization. For example, recent work demonstrates the 
feasibility of single-scan 2D Laplace NMR experiments of dissolved HP propene,[236] and 
the method should be applicable, e.g., for the investigation of dynamics and physical 
environments of HP gases in porous media, both with high-field and low-field (mobile) 
NMR instruments.[236–237]
11. Conclusion
The development and applications of HP gases continue to advance, and show no sign of 
slowing down. In addition to SEOP hyperpolarization for production of HP 3He and 129Xe, 
(i) the SEOP HP technique has been expanded to several other noble gases, (ii) the 
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heterogeneous PHIP[28a] technique has enabled production of HP hydrocarbons in pure form 
(free from contamination by the catalyst), and (iii) the dissolution DNP technique was 
demonstrated for production of HP 129Xe[26, 54a] and 15N2O gases.[238] Thus, many other 
gases could be potentially amenable to DNP hyperpolarization.
As a result of these fundamental advances in the physics, chemistry and engineering of 
hyperpolarization processes, which enabled more efficient production of established HP 
gases (e.g. higher throughput and greater polarization in 129Xe hyperpolarizers[44i, 239]) and 
other advances that enabled the production of new HP gases, it was possible to significantly 
expand the reach of applications of HP gases in biomedicine and other fields. For example, 
as described in this mini-review, HP 129Xe is now being employed for in vivo thermometry, 
brown fat imaging, targeted biosensors, and many other exciting applications, whereas HP 
hydrocarbons are already used for high-resolution 3D imaging, remote detection, and 
microfluidic imaging. Many other new applications will likely emerge given that HP gases 
are becoming more available to researchers, because hyperpolarization equipment is 
becoming more readily available through commercial sources (as opposed to custom made 
in the research labs of specialists, as was generally the case only one decade ago). So far, 
physicists have been the main driving force behind the development of MRI of 
hyperpolarized gases. However, before their entry into routine clinical practice, further 
research is needed to improve image quality and validate its use, qualitatively and 
quantitatively, in respiratory disease. This will undoubtedly require collaboration between 
physicists and clinicians. Moreover, the better-established applications (e.g. lung imaging 
using HP 129Xe) will likely continue to be more fully developed, to the point when studies 
will be driven by medical doctors (the ultimate users of this technology) rather than by the 
physicists and chemists who pioneered the technology and helped bring it from the proof-of-
principle stage to the clinical scale. We look forward to all of these developments with great 
excitement.
Acknowledgments
The Hyperpolarised Lung Function Imaging Facility (HILF), within the Sir Peter Mansfield Magnetic Imaging 
Centre (SPMIC) at University of Nottingham, where the M.J.B, SS and IPH undertake research into novel 
functional MRI techniques, is the beneficiary of grants provided by UK’s Medical Research Council (MRC) and 
Engineering and Physical Sciences Research Council (EPSRC). MGS thanks Burroughs Wellcome Fund Career 
Award at the Scientific Interface, Human Frontiers Science Program # RGP0050, and Heritage Medical Research 
Institute for funding. AMC thanks NIH 1F32EB021840 career award. We thank the following award for funding 
support: NSF CHE-1416268 and CHE-1416432 (EYC, BMG, IVK, KVK), NIH 1R21EB018014 and 
1R21EB020323 (EYC and BMG), DOD CDMRP BRP W81XWH-12-1-0159/BC112431 (EYC), PRMRP 
W81XWH-15-1-0271 and W81XWH-15-1-0272 (EYC, MSR, BMG), ExxonMobil Research and Engineering 
Company Knowledge Build (EYC). KVK, VVZ and IVK thank the Russian Science Foundation (grant 14–35–
00020) for support of the MRI experiments. V.-V.T. acknowledges the Academy of Finland (grant numbers 289649 
and 294027) for the financial support. Part of this work has been supported by the European Research Council 
under the European Community’s Seventh Framework Programme (FP7/2007-2013)/ERC grant agreement no. 
242710 to L.S.) and the Leibniz Association (WGL; grant SAW-2011-FMP-2 to L.S.).
References
1. a) Nikolaou P, Coffey A, Barlow M, Rosen M, Goodson B, Chekmenev E. Anal Chem. 2014; 
86:8206–8212. [PubMed: 25008290] b) Witte C, Schröder L. NMR Biomed. 2013; 26:788–802. 
[PubMed: 23033215] c) Ardenkjaer-Larsen J, Fridlund B, Gram A, Hansson G, Hansson L, Lerche 
Barskiy et al. Page 26
Chemistry. Author manuscript; available in PMC 2018 January 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
M, Servin R, Thaning M, Golman K. Proc Natl Acad Sci USA. 2003; 100:10158–10163. [PubMed: 
12930897] 
2. a) Goodson, BM., Whiting, N., Coffey, AM., Nikolaou, P., Shi, F., Gust, B., Gemeinhardt, ME., 
Shchepin, RV., Skinner, JG., Birchall, JR., Barlow, MJ., Chekmenev, EY. Hyperpolarization 
Methods for MRS. Griffiths, J.Bottomley, P., Wasylishen, RE., editors. Vol. 4. John Wiley & Sons, 
Ltd; West Sussex, UK: 2015. p. 797-810.b) Nikolaou P, Goodson B, Chekmenev E. Chem Eur J. 
2015; 21:3156–3166. [PubMed: 25470566] c) Goodson B. J Magn Reson. 2002; 155:157–216. 
[PubMed: 12036331] 
3. Hirsch ML, Kalechofsky N, Belzer A, Rosay M, Kempf JG. J Am Chem Soc. 2015; 137:8428–
8434. [PubMed: 26098752] 
4. Walker T, Happer W. Rev Mod Phys. 1997; 69:629.
5. Ward HR. Acc Chem Res. 1972; 5:18–24.
6. Mok KH, Hore PJ. Methods. 2004; 34:75–87. [PubMed: 15283917] 
7. a) Bowers C, Weitekamp D. Phys Rev Lett. 1986; 57:2645–2648. [PubMed: 10033824] b) Bowers 
C, Weitekamp D. J Am Chem Soc. 1987; 109:5541–5542.c) Eisenschmid T, Kirss R, Deutsch P, 
Hommeltoft S, Eisenberg R, Bargon J, Lawler R, Balch A. J Am Chem Soc. 1987; 109:8089–8091.
8. Adams R, Aguilar J, Atkinson K, Cowley M, Elliott P, Duckett S, Green G, Khazal I, Lopez-Serrano 
J, Williamson D. Science. 2009; 323:1708–1711. [PubMed: 19325111] 
9. a) Koptyug IV, Kovtunov KV, Burt SR, Anwar MS, Hilty C, Han SI, Pines A, Sagdeev RZ. J Am 
Chem Soc. 2007; 129:5580–5586. [PubMed: 17408268] b) Bouchard LS, Kovtunov KV, Burt SR, 
Anwar MS, Koptyug IV, Sagdeev RZ, Pines A. Angew Chem Int Ed. 2007; 46:4064–4068.
10. Goodson BM. J Magn Reson. 2002; 155:157–216. [PubMed: 12036331] 
11. a) Carver TR, Slichter CP. Phys Rev. 1953; 92:212–213.b) Overhauser A. Phys Rev. 1953; 92:411–
415.c) Natterer J, Bargon J. Prog Nucl Magn Reson Spectrosc. 1997; 31:293–315.
12. Golman K, Axelsson O, Johannesson H, Mansson S, Olofsson C, Petersson J. Magn Reson Med. 
2001; 46:1–5. [PubMed: 11443703] 
13. a) Gabellieri C, Reynolds S, Lavie A, Payne GS, Leach MO, Eykyn TR. J Am Chem Soc. 2008; 
130:4598–4599. [PubMed: 18345678] b) Reineri F, Viale A, Ellena S, Alberti D, Boi T, 
Giovenzana G, Gobetto R, Premkumar S, Aime S. J Am Chem Soc. 2012; 134:11146–11152. 
[PubMed: 22663300] c) Theis T, Truong M, Coffey A, Chekmenev E, Warren W. J Magn Reson. 
2014; 248:23–26. [PubMed: 25299767] d) Theis T, Truong M, Coffey A, Shchepin R, Waddell K, 
Shi F, Goodson B, Warren W, Chekmenev E. J Am Chem Soc. 2015; 137:1404–1407. [PubMed: 
25583142] 
14. Plaumann M, Bommerich U, Trantzschel T, Lego D, Dillenberger S, Sauer G, Bargon J, 
Buntkowsky G, Bernarding J. Chem Eur J. 2013; 19:6334–6339. [PubMed: 23526596] 
15. Zhivonitko VV, Skovpin IV, Koptyug IV. Chem Commun. 2015; 51:2506–2509.
16. Pavlovskaya GE, Cleveland ZI, Stupic KF, Basaraba RJ, Meersmann T. Proc Natl Acad Sci USA. 
2005; 102:18275–18279. [PubMed: 16344474] 
17. a) Goodson B. Concepts Magn Reson. 1999; 11:203–223.b) Walker T. J Phys Conf Ser. 
2011:012001.
18. Lilburn D, Pavlovskaya GE, Meersmann T. J Magn Reson. 2012; 229:173–186. [PubMed: 
23290627] 
19. Golman K, in’t Zandt R, Thaning M. Proc Natl Acad Sci U S A. 2006; 103:11270–11275. 
[PubMed: 16837573] 
20. a) Kurhanewicz J, Vigneron D, Brindle K, Chekmenev E, Comment A, Cunningham C, 
DeBerardinis R, Green G, Leach M, Rajan S, Rizi R, Ross B, Warren W, Malloy C. Neoplasia. 
2011; 13:81–97. [PubMed: 21403835] b) Brindle KM. J Am Chem Soc. 2015; 137:6418–6427. 
[PubMed: 25950268] c) Comment A, Merritt ME. Biochemistry. 2014; 53:7333–7357. [PubMed: 
25369537] d) Comment A. J Magn Reson. 2016; 264:39–48. [PubMed: 26920829] e) Keshari KR, 
Wilson DM. Chem Soc Rev. 2014; 43:1627–1659. [PubMed: 24363044] f) Koptyug IV. 
Mendeleev Commun. 2013; 23:299–312.g) Meier S, Jensen PR, Karlsson M, Lerche MH. Sensors. 
2014; 14:1576–1597. [PubMed: 24441771] h) Lerche MH, Jensen PR, Karlsson M, Meier S. Anal 
Chem. 2015; 87:119–132. [PubMed: 25084065] 
Barskiy et al. Page 27
Chemistry. Author manuscript; available in PMC 2018 January 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
21. a) Eshuis N, van Weerdenburg B, Feiters M, Rutjes F, Wijmenga S, Tessari M. Angew Chem Int 
Ed. 2015; 54:1481–1484.b) Hilty C, Ragavan M. Anal Chem. 2014; 87:1004–1008. [PubMed: 
25506716] 
22. Mugler J, Altes T. J Magn Reson Imaging. 2013; 37:313–331. [PubMed: 23355432] 
23. Branca R, He T, Zhang L, Floyd C, Freeman M, White C, Burant A. Proc Natl Acad Sci USA. 
2014; 111:18001–18006. [PubMed: 25453088] 
24. Schroder L. Phys Medica. 2013; 29:3–16.
25. Shapiro MG, Ramirez RM, Sperling LJ, Sun G, Sun J, Pines A, Schaffer DV, Bajaj VS. Nat Chem. 
2014; 6:629–634. [PubMed: 24950334] 
26. a) Comment A, Jannin S, Hyacinthe JN, Miéville P, Sarkar R, Ahuja P, Vasos PR, Montet X, 
Lazeyras F, Vallée JP. Phys Rev Lett. 2010; 105:018104. [PubMed: 20867484] b) Kuzma N, 
Pourfathi M, Kara H, Manasseh P, Ghosh R, Ardenkjaer-Larsen J, Kadlecek S, Rizi R. J Chem 
Phys. 2012; 137
27. Vuichoud B, Canet E, Milani J, Bornet A, Baudouin D, Veyre L, Gajan D, Emsley L, Lesage A, 
Copéret C, Thieuleux C, Bodenhausen G, Koptyug I, Jannin S. J Phys Chem Lett. 2016; 7:3235–
3239. [PubMed: 27483034] 
28. a) Bouchard LS, Burt SR, Anwar MS, Kovtunov KV, Koptyug IV, Pines A. Science. 2008; 
319:442–445. [PubMed: 18218891] b) Kovtunov KV, Beck IE, Bukhtiyarov VI, Koptyug IV. 
Angew Chem Int Ed. 2008; 47:1492–1495.
29. Kovtunov K, Zhivonitko V, Skovpin I, Barskiy D, Koptyug I. Top Curr Chem. 2013; 338:123–180. 
[PubMed: 23097028] 
30. Carravetta M, Johannessen OG, Levitt MH. Phys Rev Lett. 2004; 92:153003. [PubMed: 15169282] 
31. Brossel J, Kastler A. C R Acad Sci. 1949; 229:1213–1215.
32. Bouchiat MR, Carver TR, Varnum CM. Phys Rev Lett. 1960; 5:373–375.
33. Grover BC. Phys Rev Lett. 1978; 40:391.
34. a) Happer W, Miron E, Schaefer S, Schreiber D, Wijngaarden WV, Zeng X. Phys Rev A. 1984; 
29:3092–3110.b) Cates GD, Fitzgerald RJ, Barton AS, Bogorad P, Gatzke M, Newbury NR, Saam 
B. Phys Rev A. 1992; 45:4631–4639. [PubMed: 9907542] c) Chupp TE, Wagshul ME, Coulter KP, 
Mcdonald AB, Happer W. Phys Rev C. 1987; 36:2244–2251.
35. Meersmann, T., Brunner, E. Hyperpolarized Xenon-129 Magnetic Resonance: Concepts, 
Production, Techniques and Applications. RSC Publishing; Cambridge, UK: 2015. 
36. Nikolaou P, Goodson BM, Chekmenev EY. Chem Eur J. 2015; 21:3156–3166. [PubMed: 
25470566] 
37. a) Chupp TE, Coulter KP. Phys Rev Lett. 1985; 55:1074. [PubMed: 10031721] b) Stoner R, 
Walsworth R. Phys Rev A. 2002; 66:032704.
38. Pavlovskaya GE, Cleveland ZI, Stupic KF, Basaraba RJ, Meersmann T. Proc Natl Acad Sci USA. 
2005; 102:18275–18279. [PubMed: 16344474] 
39. Stupic KF, Cleveland ZI, Pavlovskaya GE, Meersmann T. J Magn Reson. 2011; 208:58–69. 
[PubMed: 21051249] 
40. Steck, D. Rubidium 85 D line data, Rubidium 87 D line data (revision 2.1.5, 13 January 2015). 
41. a) Babcock E, Chann B, Nelson IA, Walker TG. Appl Opt. 2005; 44:3098–3104. [PubMed: 
15929304] b) Whiting N, Nikolaou P, Eschmann N, Barlow M, Lammert R, Ungar J, Hu W, 
Vaissie L, Goodson B. Appl Phys B. 2012; 106:775–788.
42. Babcock E, Nelson I, Kadlecek S, Driehuys B, Anderson LW, Hersman FW, Walker TG. Phys Rev 
Lett. 2003; 91:123003. [PubMed: 14525358] 
43. a) Zeng XZ, Wu CJ, Zhao MX, Li SL, Li LY, Zhang XT, Liu ZD, Liu WY. Chem Phys Lett. 1991; 
182:538–540.b) Whiting N, Eschmann NA, Goodson BM, Barlow MJ. Phys Rev A. 2011; 
83:053428.
44. a) Raftery D, Long H, Meersmann T, Grandinetti PJ, Reven L, Pines A. Phys Rev Lett. 1991; 
66:584–587. [PubMed: 10043847] b) Rosen MS, Chupp TE, Coulter KP, Welsh RC, Swanson SD. 
Rev Sci Instrum. 1999; 70:1546.c) Ruth U, Hof T, Schmidt J, Fick D, Jänsch HJ. Appl Phys B. 
1999; 68:93–97.d) Desvaux H, Gautier T, Le Goff G, Pétro M, Berthault P. Eur Phys J B. 2000; 
12:289–296.e) Nikolaou P, Whiting N, Eschmann NA, Chaffee KE, Goodson BM. J Magn Reson. 
Barskiy et al. Page 28
Chemistry. Author manuscript; available in PMC 2018 January 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
2009; 197:249–254. [PubMed: 19162517] f) Parnell SR, Deppe MH, Parra-Robles J, Wild JM. J 
Appl Phys. 2010; 108:064908.g) Whiting N, Nikolaou P, Eschmann NA, Goodson BM, Barlow 
MJ. J Magn Reson. 2011; 208:298–304. [PubMed: 21185208] h) Six JS, Hughes-Riley T, Stupic 
KF, Pavlovskaya GE, Meersmann T. PloS One. 2012; 7:49927.i) Nikolaou P, Coffey A, Walkup L, 
Gust B, Whiting N, Newton H, Barcus S, Muradyan I, Dabaghyan M, Moroz G, Rosen M, Patz S, 
Barlow M, Chekmenev E, Goodson B. Proc Natl Acad Sci USA. 2013; 110:14150–14155. 
[PubMed: 23946420] j) Hughes-Riley T, Six JS, Lilburn DM, Stupic KF, Dorkes AC, Shaw DE, 
Pavlovskaya GE, Meersmann T. J Magn Reson. 2013; 237:23–33. [PubMed: 24135800] 
45. a) Driehuys B, Cates G, Miron E, Sauer K, Walter D, Happer W. Appl Phys Lett. 1996; 69:1668–
1670.b) Haake M, Pines A, Reimer JA, Seydoux R. J Am Chem Soc. 1997; 119:11711–11712.c) 
Zook AL, Adhyaru BB, Bowers CR. J Magn Reson. 2002; 159:175–182. [PubMed: 12482697] d) 
Mortuza MG, Anala S, Pavlovskaya GE, Dieken TJ, Meersmann T. J Chem Phys. 2003; 
181:1581.e) Knagge K, Prange J, Raftery D. Chem Phys Lett. 2004; 397:11–16.f) Ruset IC, Ketel 
S, Hersman FW. Phys Rev Lett. 2006; 96:053002. [PubMed: 16486926] g) Schrank G, Ma Z, 
Schoeck A, Saam B. Phys Rev A. 2009; 80:063424.h) Norquay G, Parnell SR, Xu X, Parra-Robles 
J, Wild JM. J Appl Phys. 2013; 113:044908.i) Nossov A, Haddad E, Guenneaua F, Gédéon A. 
Phys Chem Chem Phys. 2003; 5:4473–4478.
46. a) Stupic KF, Cleveland ZI, Pavlovskaya GE, Meersmann T. Solid State Nucl Magn Reson. 2006; 
29:79–84. [PubMed: 16202568] b) Wu Z, Happer W, Kitano M, Daniels J. Phys Rev A. 1990; 
42:2774. [PubMed: 9904348] c) Ghosh, RK. Spin Exchange Optical Pumping of Neon and its 
Applications. Princeton University; 2009. d) Fain S, Schiebler ML, McCormack DG, Parraga G. J 
Magn Reson Imaging. 2010; 32:1398–1408. [PubMed: 21105144] 
47. Cates GD, Benton DR, Gatzke M, Happer W, Hasson KC, Newbury NR. Phys Rev Lett. 1990; 
65:2591–2594. [PubMed: 10042636] 
48. a) Chann B, Nelson I, Walker TG. Opt Lett. 2000; 25:1352–1354. [PubMed: 18066214] b) Zerger 
JN, Lim MJ, Coulter KP, Chupp TE. Appl Phys Lett. 2000; 76:1798–1800.
49. Colegrove FD, Scheare LD, Walters GK. Phys Rev. 1963; 132:2561–2572.
50. a) Gentile TR, Rich DR, Thompson AK, Snow WM, Jones GL. J Res Natl Inst Stand Technol. 
2001; 106:709–729. [PubMed: 27500044] b) Nacher PJ, Tastevin G, Maitre X, Dollat X, Lemaire 
B, Olejnik J. Eur J Radiol. 1999; 9:b18.
51. Ebert M, Grossmann T, Heil W, Otten WE, Surkau R, Leduc M, Bachert P, Knopp MV, Schad LR, 
Thelen M. Lancet. 1996; 11:9011.
52. a) Schearer LD. Phys Rev. 1969; 180:83–90.b) Young L, Yang D, Dunford RW. J Phys B. 2002; 
35:2985–2992.c) Hadeishi T, Chung-Heng L. Phys Rev Lett. 1967; 19:211.d) Lefevre-Seguin V, 
Leduc M. J Phys B. 1977; 10:2157.
53. a) Frossati G. J Low Temp Phys. 1998; 111:521–532.b) Tanaka M, Kunimatsu T, Fujiwara M, 
Kohri H, Ohta T, Utsuro M, Yosoi M, Ono S, Fukuda K, Takamatsu K, Ueda K, Didelez J-P, 
Frossati G, Waard Ad. J Phys: Conf Ser. 2011; 295:012167.c) O’Neill JD, Krjukov EV, Owers-
Bradley JR, Xia Y. J Low Temp Phys. 2007; 146:563–579.d) Krjukov EV, O’Neill JD, Owers-
Bradley JR. J Low Temp Phys. 2005; 140:397–408.
54. a) Pourfathi M, Kuzma NN, Kara H, Ghosh RK, Shaghaghi H, Kadlecek SJ, Rizi RR. J Magn 
Reson. 2013; 253:71–76.b) Capozzi A, Roussel C, Comment A, Hyacinthe JN. J Phys Chem C. 
2015; 119:5020–5025.c) Capozzi A, Hyacinthe JN, Cheng T, Eichhorn TR, Boero G, Roussel C, 
van der Klink JJ, Comment A. J Phys Chem C. 2015; 119:22632–22639.
55. Ardenkjaer-Larsen JH, Leach AM, Clarke N, Urbahn J, Anderson D, Skloss TW. NMR Biomed. 
2011; 24:927–932. [PubMed: 21416540] 
56. a) Chupp TE, Hoare RJ, Walsworth RL, Wu B. Phys Rev Lett. 1994; 72:2363. [PubMed: 
10055861] b) Newbury NR, Barton AS, Bogorad P, Cates GD, Gatzke M, Saam B, Han L, Holmes 
R, Souder PA, Xu J, Benton D. Phys Rev Lett. 1991; 67:3219. [PubMed: 10044677] 
57. a) Thompson AK, Bernstein AM, Chupp TE, DeAngelis DJ, Dodge GE, Dodson G, Dow KA, 
Farkhondeh M, Fong W, Kim JY, Loveman RA, Richardson JM, Schmieden H, Tieger DR, Yates 
TC, Wagshul ME, Zumbro JD. Phys Rev Lett. 1992; 68:2901. [PubMed: 10045524] b) Singh JT, 
Dolph PAM, Tobias WA, Averett TD, Kelleher A, Mooney KE, Nelyubin VV, Wang Y, Zheng Y, 
Cates GD. Phys Rev C. 2015; 91:055205.c) Lelievre-Berna E. Physica B Cond Mat. 2007; 
397:162–167.d) Gentile TR, Chen WC. Proc Sci (PSTP). 2013; 022:1–11.e) Karpuk S, 
Barskiy et al. Page 29
Chemistry. Author manuscript; available in PMC 2018 January 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Allmendinger F, Burghoff M, Gemmel C, Güldner M, Heil W, Kilian W, Knappe-Grüneberg S, 
Mrozik C, Müller W, Otten EW, Repetto M, Salhi Z, Schmidt U, Schnabel A, Seifert F, Sobolev Y, 
Trahms L, Tullney K. Phys Part Nucl. 2013; 44:904–908.
58. a) Raftery D, Reven L, Long H, Pines A, Tang P, Reimer JA. J Phys Chem. 1993; 97:1649–1655.b) 
Bowers CR, Pietrass T, Barash E, Pines A, Grubbs RK, Alivisatos AP. J Phys Chem. 1994; 
98:9400–9404.c) Pietrass T, Bifone A, Pines A. Surf Sci. 1995; 334:L730–L734.
59. a) Bowers CR, Long HW, Pietrass T, Gaede HC, Pines A. Chem Phys Lett. 1993; 205:168–170.b) 
Driehuys B, Cates GD, Happer W, Mabuchi H, Saam B, Albert MS, Wishnia A. Phys Lett A. 
1993; 184:88–92.c) Long HW, Gaede HC, Shore J, Reven L, Bowers CR, Kritzenberger J, Pietrass 
T, Pines A, Tang P, Reimer JA. J Am Chem Soc. 1993; 115:8491–8492.d) Driehuys B, Cates GD, 
Happer W. Phys Rev Lett. 1995; 74:4943–4946. [PubMed: 10058638] e) Gaede HC, Song YQ, 
Taylor RE, Munson EJ, Reimer JA, Pines A. Appl Magn Reson. 1995; 8:373–384.f) Room T, 
Appelt S, Seydoux R, Hahn EL, Pines A. Phys Rev B. 1997; 55:11604–11610.g) Navon G, Song 
YQ, Room T, Appelt S, Taylor RE, Pines A. Science. 1996; 271:1848–1851.h) Fitzgerald RJ, 
Sauer KL, Happer W. Chem Phys Lett. 1998; 284:87–92.i) Pietrass T, Seydoux R, Pines A. J 
Magn Reson. 1998; 133:299–303. [PubMed: 9716472] j) Appelt S, Haesing F, Baer-Lang S, Shah 
N, Blumich B. Chem Phys Lett. 2001; 348:263–269.
60. a) Haake M, Pines A, Reimer JA, Seydoux R. J Am Chem Soc. 1997; 119:11711–11712.b) 
Seydoux R, Pines A, Haake M, Reimer JA. J Phys Chem B. 1999; 103:4629–4637.c) 
Moudrakovski IL, Nossov A, Lang S, Breeze SR, Ratcliffe CI, Simard B, Santyr G, Ripmeester 
JA. Chem Mater. 2000; 12:1181–1183.
61. a) Raftery D, MacNamara E, Fisher G, Rice CV, Smith J. J Am Chem Soc. 1997; 119:8746–
8747.b) Brunner E, Haake M, Pines A, Reimer JA, Seydoux R. Chem Phys Lett. 1998; 290:112–
116.c) Brunner E, Seydoux R, Haake M, Pines A, Reimer JA. J Magn Reson. 1998; 130:145–148. 
[PubMed: 9469911] d) MacNamara E, Fisher G, Smith J, Rice CV, Hwang SJ, Raftery D. J Phys 
Chem B. 1999; 103:1158–1160.
62. a) Saam B, Drukker N, Happer W. Chem Phys Lett. 1996; 263:481–487.b) Schmidt DM, George 
JS, Penttila SI, Caprihan A, Fukushima E. J Magn Reson. 1997; 129:184–187. [PubMed: 
9441883] c) Song Y, Goodson B, Sheridan B, de Swiet T, Pines A. J Chem Phys. 1998; 108:6233–
6239.
63. a) Mair RW, Cory DG, Peled S, Tseng CH, Patz S, Walsworth RL. J Magn Reson. 1998; 135:478–
486. [PubMed: 9878475] b) Mair RW, Wong GP, Hoffmann D, Hurlimann MD, Patz S, Schwartz 
LM, Walsworth RL. Phys Rev Lett. 1999; 83:3324–3327. [PubMed: 11543587] c) Peled S, Tseng 
CH, Sodickson AA, Mair RW, Walsworth RL, Cory DG. J Magn Reson. 1999; 140:320–324. 
[PubMed: 10497039] 
64. a) Moudrakovski IL, Sanchez A, Ratcliffe CI, Ripmeester JA. J Phys Chem B. 2000; 104:7306–
7310.b) Wong GP, Mair RW, Walsworth RL, Cory DG. Phys Rev Lett. 2001; 86:4156–4159. 
[PubMed: 11328119] 
65. a) Brunner E, Haake M, Kaiser L, Pines A, Reimer JA. J Magn Reson. 1999; 138:155–159. 
[PubMed: 10329238] b) Kaiser LG, Meersmann T, Logan JW, Pines A. Proc Natl Acad Sci USA. 
2000; 97:2414–2418. [PubMed: 10706617] 
66. a) Moudrakovski IL, Lang S, Ratcliffe CI, Simard B, Santyr G, Ripmeester JA. J Magn Reson. 
2000; 144:372–377. [PubMed: 10828205] b) Pavlovskaya G, Six J, MT, Gopinathan N, Rigby SP. 
AlChE J. 2015; 61:4013–4019.
67. a) Jansch HJ, Hof T, Ruth U, Schmidt J, Stahl D, Fick D. Chem Phys Lett. 1998; 296:146–150.b) 
Jansch HJ, Gerhard P, Koch M. Proc Natl Acad Sci USA. 2004; 101:13715–13719. [PubMed: 
15361579] 
68. a) Li XX, Newberry C, Saha I, Nikolaou P, Whiting N, Goodson BM. Chem Phys Lett. 2006; 
419:233–239.b) Truxal AE, Slack CC, Gomes MD, Vassiliou CC, Wemmer DE, Pines A. Angew 
Chem Int Ed. 2016; 55:4666.
69. a) Anala S, Pavlovskaya GE, Pichumani P, Dieken TJ, Olsen MD, Meersmann T. J Am Chem Soc. 
2003; 125:13298–13302. [PubMed: 14570507] b) Rogers NJ, Hill-Casey F, Stupic KF, et al. Proc 
Natl Acad Sci USA. 2016; 113:3164–3168. [PubMed: 26961001] 
70. a) Meersmann T, Logan JW, Simonutti R, Caldarelli S, Comotti A, Sozzani P, Kaiser LG, Pines A. 
J Phys Chem A. 2000; 104:11665–11670.b) Sozzani P, Comotti A, Simonutti R, Meersmann T, 
Barskiy et al. Page 30
Chemistry. Author manuscript; available in PMC 2018 January 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Logan JW, Pines A. Angew Chem Int Ed. 2000; 39:2695–2698.c) Moudrakovski I, Soldatov DV, 
Ripmeester JA, Sears DN, Jameson CJ. Proc Natl Acad Sci USA. 2004; 101:17924–17929. 
[PubMed: 15596727] d) Soldatov DV, Moudrakovski IL, Grachev EV, Ripmeester JA. J Am Chem 
Soc. 2006; 128:6737–6744. [PubMed: 16704277] e) Cheng CY, Bowers CR. J Am Chem Soc. 
2007; 129:13997–14002. [PubMed: 17944465] f) Cheng CY, Bowers CR. ChemPhysChem. 2007; 
8:2077–2081. [PubMed: 17763483] g) Cheng CY, Stamatatos TC, Christou G, Bowers CR. J Am 
Chem Soc. 2010; 132:5387–5393. [PubMed: 20349986] h) Bowers CR, Dvoyashkin M, Salpage 
SR, Akel C, Bhase H, Geer MF, Shimizu LS. ACS Nano. 2015; 9:6343–6353. [PubMed: 
26035000] i) Anedda R, Soldatov DV, Moudrakovski IL, Casu M, Ripmeester JA. Chem Mater. 
2008; 20:2908–2920.
71. Comotti A, Bracco S, Ferretti L, Mauri M, Simonutti R, Sozzani P. Chem Commun. 2007:350–
352.
72. Kneller JM, Soto RJ, Surber SE, Colomer JF, Fonseca A, Nagy JB, Van Tendeloo G, Pietrass T. J 
Am Chem Soc. 2000; 122:10591–10597.
73. Moudrakovski IL, Sanchez AA, Ratcliffe CI, Ripmeester JA. J Phys Chem B. 2001; 105:12338–
12347.
74. a) Nossov AV, Soldatov DV, Ripmeester JA. J Am Chem Soc. 2001; 123:3563–3568. [PubMed: 
11472127] b) Butler JP, Mair RW, Hoffmann D, Hrovat MI, Rogers RA, Topulos GP, Walsworth 
RL, Patz S. J Phys Condens Matter. 2002; 14:L297–L304. [PubMed: 12741395] c) Moudrakovski 
IL, Wang LQ, Baumann T, Satcher JH, Exarhos GJ, Ratcliffe CI, Ripmeester JA. J Am Chem Soc. 
2004; 126:5052–5053. [PubMed: 15099072] d) Moudrakovski IL, Ratcliffe CI, Ripmeester JA, 
Wang LQ, Exarhos GJ, Baumann TF, Satcher JH. J Phys Chem B. 2005; 109:11215–11222. 
[PubMed: 16852369] e) Simonutti R, Bracco S, Comotti A, Mauri M, Sozzani P. Chem Mater. 
2006; 18:4651–4657.f) Comotti A, Bracco S, Sozzani P, Horike S, Matsuda R, Chen J, Takata M, 
Kubota Y, Kitagawa S. J Am Chem Soc. 2008; 130:13664–13672. [PubMed: 18798624] 
75. a) Campbell K, Ooms KJ, Wasylishen RE, Tykwinski RR. Org Lett. 2005; 7:3397–3400. [PubMed: 
16048301] b) Ooms KJ, Wasylishen RE. Microporous Mesoporous Mater. 2007; 103:341–351.c) 
Pawsey S, Moudrakovski I, Ripmeester J, Wang LQ, Exarhos GJ, Rowsell JLC, Yaghi OM. J Phys 
Chem C. 2007; 111:6060–6067.
76. a) Dubes A, Moudrakovski IL, Shahgaldian P, Coleman AW, Ratcliffe CI, Ripmeester JA. J Am 
Chem Soc. 2004; 126:6236–6237. [PubMed: 15149213] b) Ananchenko GS, Moudrakovski IL, 
Coleman AW, Ripmeester JA. Angew Chem Int Ed. 2008; 47:5616–5618.
77. Sozzani P, Bracco S, Comotti A, Mauri M, Simonutti R, Valsesia P. Chem Commun. 2006:1921–
1923.
78. a) Nossov A, Haddad E, Guenneau F, Mignon C, Gedeon A, Grosso D, Babonneau F, Bonhomme 
C, Sanchez C. Chem Commun. 2002:2476–2477.b) Terskikh VV, Moudrakovski IL, Breeze SR, 
Lang S, Ratcliffe CI, Ripmeester JA, Sayari A. Langmuir. 2002; 18:5653–5656.c) Nossov A, 
Haddad E, Guenneau F, Galarneau A, Di Renzo F, Fajula F, Gedeon A. J Phys Chem B. 2003; 
107:12456–12460.d) Comotti A, Bracco S, Valsesia P, Ferretti L, Sozzani P. J Am Chem Soc. 
2007; 129:8566–8576. [PubMed: 17579407] e) Galarneau A, Nader M, Guenneau F, Di Renzo F, 
Gedeon A. J Phys Chem C. 2007; 111:8268–8277.
79. a) Nossov A, Guenneau F, Springuel-Huet MA, Haddad E, Montouillout V, Knott B, Engelke F, 
Fernandez C, Gedeon A. Phys Chem Chem Phys. 2003; 5:4479–4483.b) Sakthivel A, Huang SJ, 
Chen WH, Lan ZH, Chen KH, Kim TW, Ryoo R, Chiang AST, Liu SB. Chem Mater. 2004; 
16:3168–3175.c) Sakthivel A, Huang SJ, Chen WH, Lan ZH, Chen KH, Lin HP, Mou CY, Liu SB. 
Adv Funct Mater. 2005; 15:253–258.d) Liu Y, Zhang WP, Liu ZC, Xu ST, Wang YD, Xie ZK, Han 
XW, Bao XH. J Phys Chem C. 2008; 112:15375–15381.e) Liu Y, Zhang WP, Xie SJ, Xu L, Han 
XW, Bao XH. J Phys Chem B. 2008; 112:1226–1231. [PubMed: 18181607] f) Itani L, Liu Y, 
Zhang WP, Bozhilov KN, Delmotte L, Valtchev V. J Am Chem Soc. 2009; 131:10127–10139. 
[PubMed: 19572709] g) Xin HC, Zhao J, Xu ST, Li JP, Zhang WP, Guo XW, Hensen EJM, Yang 
QH, Li C. J Phys Chem C. 2010; 114:6553–6559.h) Zhu KK, Sun JM, Liu J, Wang LQ, Wan HY, 
Hu JZ, Wang Y, Peden CHF, Nie ZM. ACS Catal. 2011; 1:682–690.i) Jin CZ, Li G, Wang XS, 
Zhao LX, Liu LP, Liu HO, Liu Y, Zhang WP, Han XW, Bao XH. Chem Mater. 2007; 19:1664–
1670.j) Li XJ, Zhang WP, Liu SL, Xu LY, Han XW, Bao XH. J Catal. 2007; 250:55–66.
80. a) Jameson CJ. J Chem Phys. 2002; 116:8912–8929.b) Jameson CJ, de Dios AC. J Chem Phys. 
2002; 116:3805–3821.
Barskiy et al. Page 31
Chemistry. Author manuscript; available in PMC 2018 January 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
81. Weiland E, Springuel-Huet MA, Nossov A, Gédéon A. Microporous Mesoporous Mater. 2016; 
225:41–65.
82. Woods, JC. Congressional Hearing: “Caught by Surprise: Causes and Consequences of the 
Helium-3 Supply Crisis”. 2010. 
83. a) Six JS, Hughes-Riley T, Lilburn DM, Dorkes AC, Stupic KF, Shaw DE, Morris PG, Hall IP, 
Pavlovskaya GE, Meersmann T. Magn Reson Imag. 2014; 32:48–53.b) Cleveland ZI, Stupic KF, 
Pavlovskaya GE, Repine JE, Wooten JB, Meersmann T. J Am Chem Soc. 2007; 129:1784–1792. 
[PubMed: 17243679] 
84. Ramsay W. Nobel lecture. Dec.1904 12:1901–1921.
85. Marx T, Schmidt M, Schirmer U, Reinelt H. J R Soc Med. 2000; 93:513–517. [PubMed: 
11064688] 
86. Lawrence J, Loomis W, Tobias C, Turpin F. J Physiol. 1946; 105:197.
87. Cullen SC, Gross EG. Science. 1951; 113:580–582. [PubMed: 14834873] 
88. Albert M, Cates G, Driehuys B, Happer W, Saam B, Springer C, Wishnia A. Nature. 1994; 
370:199–201. [PubMed: 8028666] 
89. a) Edelman R, Hatabu H, Tadamura E, Li W, Prasad P. Nat Med. 1996; 2:1236–1239. [PubMed: 
8898751] b) Kauczor H, Kreitner K. Eur Radiol. 1999; 9:1755–1764. [PubMed: 10602947] 
90. Mugler J, Driehuys B, Brookeman J, Cates G, Berr S, Bryant R, Daniel T, deLange E, Downs J, 
Erickson C, Happer W, Hinton D, Kassel N, Maier T, Phillips C, Saam B, Sauer K, Wagshul M. 
Magn Reson Med. 1997; 37:809–815. [PubMed: 9178229] 
91. Zhao L, Albert M. Nucl Instrum Meth A. 1998; 402:454–460.
92. a) Middleton H, Black R, Saam B, Cates G, Cofer G, Guenther R, Happer W, Hedlund L, Johnson 
G, Juvan K, Swartz J. Magn Reson Med. 1995; 33:271–275. [PubMed: 7707920] b) Walkup L, 
Woods J. NMR Biomed. 2014; 27:1429–1438. [PubMed: 24953709] 
93. a) Shukla Y, Wheatley A, Kirby M, Svenningsen S, Farag A, Santyr G, Paterson N, McCormack D, 
Parraga G. Acad Radiol. 2012; 19:941–951. [PubMed: 22591724] b) Svenningsen S, Kirby M, 
Starr D, Leary D, Wheatley A, Maksym GN, McCormack DG, Parraga G. J Magn Reson Imaging. 
2013; 38:1521–1530. [PubMed: 23589465] 
94. a) Kaushik SS, Cleveland ZI, Cofer GP, Metz G, Beaver D, Nouls J, Kraft M, Auffermann W, 
Wolber J, McAdams HP. Magn Reson Med. 2011; 65:1154–1165. [PubMed: 21413080] b) 
Driehuys B, Martinez-Jimenez S, Cleveland Z, Metz G, Beaver D, Nouls J, Kaushik S, Firszt R, 
Willis C, Kelly K, Wolber J, Kraft M, McAdams H. Radiology. 2012; 262:279–289. [PubMed: 
22056683] c) Kirby M, Svenningsen S, Owrangi A, Wheatley A, Farag A, Ouriadov A, Santyr G, 
Etemad-Rezai R, Coxson H, McCormack D, Parraga G. Radiology. 2012; 265:600–610. [PubMed: 
22952383] d) Kirby M, Svenningsen S, Kanhere N, Owrangi A, Wheatley A, Coxson H, Santyr G, 
Paterson N, McCormack D, Parraga G. J Appl Physiol. 2013; 114:707–715. [PubMed: 23239874] 
95. a) Kaushik S, Freeman M, Yoon S, Liljeroth M, Stiles J, Roos J, Foster W, Rackley C, McAdams 
H, Driehuys B. J Appl Physiol. 2014; 117:577–585. [PubMed: 25038105] b) Stewart NJ, Leung G, 
Norquay G, Marshall H, Parra-Robles J, Murphy PS, Schulte RF, Elliot C, Condliffe R, Griffiths 
PD. Magn Reson Med. 2015; 74:196–207.
96. Kaushik S, Cleveland Z, Cofer G, Metz G, Beaver D, Nouls J, Kraft M, Auffermann W, Wolber J, 
McAdams H, Driehuys B. Magn Reson Med. 2011; 65:1155–1165.
97. Kirby M, Parraga G. Acad Radiol. 2013; 20:1344–1356. [PubMed: 24119346] 
98. Zeiher BG, Gross TJ, Kern JA, Lanza LA, Peterson MW. Chest. 1995; 108:68–72. [PubMed: 
7606994] 
99. a) Ruppert K, Brookeman J, Hagspiel K, Mugler J. Magn Reson Med. 2000; 44:349–357. 
[PubMed: 10975884] b) Butler J, Mair R, Hoffmann D, Hrovat M, Rogers R, Topulos G, 
Walsworth R, Patz S. J Phys Condens Matter. 2002; 14:L297. [PubMed: 12741395] c) Möller HE, 
Chen XJ, Saam B, Hagspiel KD, Johnson GA, Altes TA, De Lange EE, Kauczor HU. Magn Reson 
Med. 2002; 47:1029–1051. [PubMed: 12111949] 
100. Qing K, Ruppert K, Jiang Y, Mata J, Miller W, Shim Y, Wang C, Ruset I, Hersman F, Altes T, 
Mugler J. J Magn Reson Imaging. 2014; 39:346–359. [PubMed: 23681559] 
101. Cleveland Z, Cofer G, Metz G, Beaver D, Nouls J, Kaushik S, Kraft M, Wolber J, Kelly K, 
McAdams H, Driehuys B. Plos One. 2010; 5(8):e12192. [PubMed: 20808950] 
Barskiy et al. Page 32
Chemistry. Author manuscript; available in PMC 2018 January 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
102. a) Mugler J, Altes T, Ruset I, Dregely I, Mata J, Miller G, Ketel S, Ketel J, Hersman F, Ruppert K. 
Proc Natl Acad Sci USA. 2010; 107:21707–21712. [PubMed: 21098267] b) Chang YV, Quirk 
JD, Ruset IC, Atkinson JJ, Hersman FW, Woods JC. Magn Reson Med. 2014; 71:339–344. 
[PubMed: 24155277] c) Ruppert K, Mata J, Brookeman J, Hagspiel K, Mugler J. Magn Reson 
Med. 2004; 51:676–687. [PubMed: 15065239] d) Ruppert K, Mata J, Wang H, Tobias W, Cates 
G, Brookeman J, Hagspiel K, Mugler J. Magn Reson Med. 2007; 57:1099–1109. [PubMed: 
17534927] Chang, Y., Mata, J., Altes, T., Mugler, J., III, Ruppert, K. Proceedings of the Joint 
Annual Meeting of ISMRM-ESMRMB; Stockholm, Sweden. 2010. p. 4602
103. a) Chang YV. Magn Reson Med. 2013; 69:884–890. [PubMed: 22565296] b) Dregely I, Ruset I, 
Mata J, Ketel J, Ketel S, Distelbrink J, Altes T, Mugler J, Miller G, Hersman F, Ruppert K. Magn 
Reson Med. 2012; 67:943–953. [PubMed: 22213334] c) Dregely I, Mugler J, Ruset I, Altes T, 
Mata J, Miller G, Ketel J, Ketel S, Distelbrink J, Hersman F, Ruppert K. J Magn Reson Imaging. 
2011; 33:1052–1062. [PubMed: 21509861] 
104. Chen R, Fan F-C, Kim S, Jan K, Usami S, Chien S. J Appl Physiol. 1980; 49:178–183. [PubMed: 
7400000] 
105. Gur D, Good WF, Wolfson SK, Yonas H, Shabason L. Science. 1982; 215:1267–1268. [PubMed: 
7058347] 
106. Swanson SD, Rosen MS, Agranoff BW, Coulter KP, Welsh RC, Chupp TE. Magn Reson Med. 
1997; 38:695–698. [PubMed: 9358441] 
107. a) Wakai A, Nakamura K, Kershaw J, Kondoh Y, Wright D, Kanno I. Magn Reson Med Sci. 
2005; 4:19–25. [PubMed: 16127250] b) Zhou X, Mazzanti M, Chen J, Tzeng YS, Mansour J, 
Gereige J, Venkatesh A, Sun Y, Mulkern R, Albert M. NMR Biomed. 2008; 21:217–225. 
[PubMed: 17557274] 
108. Duhamel G, Choquet P, Leviel J-L, Steibel J, Lamalle L, Julien C, Kober F, Grillon E, Derouard J, 
Décorps M. C R Acad Sci. 2000; 323:529–536. [PubMed: 10923208] 
109. Zhou X, Sun Y, Mazzanti M, Henninger N, Mansour J, Fisher M, Albert M. NMR Biomed. 2011; 
24:170–175. [PubMed: 20821723] 
110. Mazzanti M, Walvick R, Zhou X, Sun Y, Shah N, Mansour J, Gereige J, Albert M. Plos One. 
2011; 6(7):e21607. [PubMed: 21789173] 
111. Kety SS. Pharmacol Rev. 1951; 3:1–41. [PubMed: 14833874] 
112. Landon C, Berthault P, Vovelle F, Desvaux H. Prot Sci. 2001; 10:762–770.
113. Rubin SM, Lee S-Y, Ruiz EJ, Pines A, Wemmer DE. J Mol Biol. 2002; 322:425–440. [PubMed: 
12217701] 
114. Bifone A, Song Y, Seydoux R, Taylor R, Goodson B, Pietrass T, Budinger T, Navon G, Pines A. 
Proc Natl Acad Sci USA. 1996; 93:12932–12936. [PubMed: 8917521] 
115. a) Gunawardana SC, Piston DW. Diabetes. 2012; 61:674–682. [PubMed: 22315305] b) Liu X, 
Wang S, You Y, Meng M, Zheng Z, Dong M, Lin J, Zhao Q, Zhang C, Yuan X. Endocrinology. 
2015; 156:2461–2469. [PubMed: 25830704] 
116. Cypess AM, Haft CR, Laughlin MR, Hu HH. Cell Metab. 2014; 20:408–415. [PubMed: 
25185947] 
117. Thurlby P, Trayhurn P. Pflügers Archiv. 1980; 385:193–201. [PubMed: 7190682] 
118. Branca, R., Zhang, L., Burant, A., Katz, L., McCallister, A. Proceedings of the 24th Annual 
Meeting ISMRM; Singapore. 2016. p. 1054
119. Schoenborn BP, Watson HC, Kendrew JC. Nature. 1965; 207:28–30. [PubMed: 5893727] 
120. Bowers C, Storhaug V, Webster CE, Bharatam J, Cottone A, Gianna R, Betsey K, Gaffney B. J 
Am Chem Soc. 1999; 121:9370–9377. [PubMed: 16429610] 
121. Dubois L, Da Silva P, Landon C, Huber JG, Ponchet M, Vovelle F, Berthault P, Desvaux H. J Am 
Chem Soc. 2004; 126:15738–15746. [PubMed: 15571396] 
122. Rubin SM, Spence MM, Dimitrov IE, Ruiz EJ, Pines A, Wemmer DE. J Am Chem Soc. 2001; 
123:8616–8617. [PubMed: 11525678] 
123. Lowery TJ, Doucleff M, Ruiz EJ, Rubin SM, Pines A, Wemmer DE. Prot Sci. 2005; 14:848–855.
124. Lowery TJ, Rubin SM, Ruiz EJ, Pines A, Wemmer DE. Angew Chem Int Ed. 2004; 43:6320–
6322.
Barskiy et al. Page 33
Chemistry. Author manuscript; available in PMC 2018 January 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
125. Song Y, Goodson B, Taylor R, Laws D, Navon G, Pines A. Angew Chem Int Ed. 1997; 36:2368–
2370.
126. a) El Haouaj M, Luhmer M, Ko YH, Kim K, Bartik K. J Chem Soc, Perkin Trans. 2001; 2:804–
807.b) Huber G, Legrand FX, Lewin V, Baumann D, Heck MP, Berthault P. ChemPhysChem. 
2011; 12:1053–1055. [PubMed: 21404420] 
127. a) Bartik K, Luhmer M, Dutasta JP, Collet A, Reisse J. J Am Chem Soc. 1998; 120:784–791.b) 
Luhmer M, Goodson B, Song Y, Laws D, Kaiser L, Cyrier M, Pines A. J Am Chem Soc. 1999; 
121:3502–3512.
128. a) Spence MM, Rubin SM, Dimitrov IE, Ruiz EJ, Wemmer DE, Pines A, Yao SQ, Tian F, Schultz 
PG. Proc Natl Acad Sci USA. 2001; 98:10654–10657. [PubMed: 11535830] b) Brotin T, Lesage 
A, Emsley L, Collet A. J Am Chem Soc. 2000; 122:1171–1174.
129. Brotin T, Dutasta J-P. Chem Rev. 2008; 109:88–130.
130. a) Hill PA, Wei Q, Eckenhoff RG, Dmochowski IJ. J Am Chem Soc. 2007; 129:9262–9263. 
[PubMed: 17616197] b) Hill PA, Wei Q, Troxler T, Dmochowski IJ. J Am Chem Soc. 2009; 
131:3069–3077. [PubMed: 19239271] c) Huber G, Brotin T, Dubois L, Desvaux H, Dutasta JP, 
Berthault P. J Am Chem Soc. 2006; 128:6239–6246. [PubMed: 16669694] 
131. a) Jacobson DR, Khan NS, Collé R, Fitzgerald R, Laureano-Pérez L, Bai Y, Dmochowski IJ. Proc 
Natl Acad Sci USA. 2011; 108:10969–10973. [PubMed: 21690357] b) Taratula O, Hill PA, Khan 
NS, Carroll PJ, Dmochowski IJ. Nat Commun. 2010; 1:148. [PubMed: 21266998] 
132. Gao L, Liu W, Lee O-S, Dmochowski IJ, Saven JG. Chem Sci. 2015; 6:7238–7248.
133. Lowery TJ, Garcia S, Chavez L, Ruiz EJ, Wu T, Brotin T, Dutasta JP, King DS, Schultz PG, Pines 
A. ChemBioChem. 2006; 7:65–73. [PubMed: 16342304] 
134. a) Canceill J, Lacombe L, Collet A. J Chem Soc, Chem Commun. 1987:219–221.b) Fairchild 
RM, Joseph AI, Holman KT, Fogarty HA, Brotin T, Dutasta J-P, Boutin Cl, Huber G, Berthault P. 
J Am Chem Soc. 2010; 132:15505–15507. [PubMed: 20958059] c) Traoré T, Clavé G, Delacour 
L, Kotera N, Renard PY, Romieu A, Berthault P, Boutin C, Tassali N, Rousseau B. Chem 
Commun. 2011; 47:9702–9704.d) Bai Y, Hill PA, Dmochowski IJ. Anal Chem. 2012; 84:9935–
9941. [PubMed: 23106513] e) Dubost E, Kotera N, Garcia-Argote S, Boulard Y, Léonce E, 
Boutin C, Berthault P, Dugave C, Rousseau B. Org Lett. 2013; 15:2866–2868. [PubMed: 
23705676] f) Tyagi R, Witte C, Haag R, Schröder L. Org Lett. 2014; 16:4436–4439. [PubMed: 
25152959] 
135. Hilty C, Lowery TJ, Wemmer DE, Pines A. Angew Chem Int Ed. 2006; 118:76–79.
136. Garcia S, Chavez L, Lowery TJ, Han S-I, Wemmer DE, Pines A. J Magn Reson. 2007; 184:72–
77. [PubMed: 17046295] 
137. Kotera N, Tassali N, Léonce E, Boutin C, Berthault P, Brotin T, Dutasta JP, Delacour L, Traoré T, 
Buisson DA. Angew Chem Int Ed. 2012; 51:4100–4103.
138. Ward K, Aletras A, Balaban R. J Magn Reson. 2000; 143:79–87. [PubMed: 10698648] 
139. Schröder L, Lowery TJ, Hilty C, Wemmer DE, Pines A. Science. 2006; 314:446–449. [PubMed: 
17053143] 
140. Kunth M, Dopfert J, Witte C, Rossella F, Schroder L. Angew Chem Int Ed. 2012; 51:8217–8220.
141. a) Schröder L, Meldrum T, Smith M, Lowery TJ, Wemmer DE, Pines A. Phys Rev Lett. 2008; 
100:257603. [PubMed: 18643704] b) Schröder L, Chavez L, Meldrum T, Smith M, Lowery TJ, 
Wemmer DE, Pines A. Angew Chem Int Ed. 2008; 47:4316–4320.
142. Schilling F, Schroder L, Palaniappan K, Zapf S, Wemmer D, Pines A. ChemPhysChem. 2010; 
11:3529–3533. [PubMed: 20821795] 
143. Wei Q, Seward GK, Hill PA, Patton B, Dimitrov IE, Kuzma NN, Dmochowski IJ. J Am Chem 
Soc. 2006; 128:13274–13283. [PubMed: 17017809] 
144. Roy V, Brotin T, Dutasta JP, Charles MH, Delair T, Mallet F, Huber G, Desvaux H, Boulard Y, 
Berthault P. ChemPhysChem. 2007; 8:2082–2085. [PubMed: 17712828] 
145. Chambers JM, Hill PA, Aaron JA, Han Z, Christianson DW, Kuzma NN, Dmochowski IJ. J Am 
Chem Soc. 2008; 131:563–569.
146. Schlundt A, Kilian W, Beyermann M, Sticht J, Günther S, Höpner S, Falk K, Roetzschke O, 
Mitschang L, Freund C. Angew Chem Int Ed. 2009; 121:4206–4209.
Barskiy et al. Page 34
Chemistry. Author manuscript; available in PMC 2018 January 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
147. Kotera N, Tassali N, Leonce E, Boutin C, Berthault P, Brotin T, Dutasta J, Delacour L, Traore T, 
Buisson D, Taran F, Coudert S, Rousseau B. Angew Chem Int Ed. 2012; 51:4100–4103.
148. Rose HM, Witte C, Rossella F, Klippel S, Freund C, Schröder L. Proc Natl Acad Sci USA. 2014; 
111:11697–11702. [PubMed: 25071165] 
149. Seward GK, Bai Y, Khan NS, Dmochowski IJ. Chem Sci. 2011; 2:1103–1110. [PubMed: 
25364495] 
150. Boutin C, Stopin A, Lenda F, Brotin T, Dutasta J-P, Jamin N, Sanson A, Boulard Y, Leteurtre F, 
Huber G. Bioorg Med Chem. 2011; 19:4135–4143. [PubMed: 21605977] 
151. Palaniappan KK, Ramirez RM, Bajaj VS, Wemmer DE, Pines A, Francis MB. Angew Chem Int 
Ed. 2013; 125:4949–4953.
152. Khan NS, Riggle BA, Seward GK, Bai Y, Dmochowski IJ. Bioconjugate Chem. 2014; 26:101–
109.
153. Witte C, Martos V, Rose H, Reinke S, Klippel S, Schroder L, Hackenberger C. Angew Chem Int 
Ed. 2015; 54:2806–2810.
154. Riggle BA, Wang Y, Dmochowski IJ. J Am Chem Soc. 2015; 137:5542–5548. [PubMed: 
25848822] 
155. Seward GK, Wei Q, Dmochowski IJ. Bioconjugate Chem. 2008; 19:2129–2135.
156. a) Klippel S, Dopfert J, Jayapaul J, Kunth M, Rossella F, Schnurr M, Witte C, Freund C, Schroder 
L. Angew Chem Int Ed. 2014; 53:493–496.b) Klippel S, Freund C, Schroder L. Nano Letters. 
2014; 14:5721–5726. [PubMed: 25247378] c) Rossella F, Rose H, Witte C, Jayapaul J, Schroder 
L. ChemPlusChem. 2014; 79:1463–1471.
157. Meldrum T, Schroder L, Denger P, Wemmer D, Pines A. J Magn Reson. 2010; 205:242–246. 
[PubMed: 20542715] 
158. Sloniec J, Schnurr M, Witte C, Resch - Genger U, Schröder L, Hennig A. Chem Eur J. 2013; 
19:3110–3118. [PubMed: 23319433] 
159. Schnurr M, Witte C, Schröder L. Phys Chem Chem Phys. 2013; 15:14178–14181. [PubMed: 
23793163] 
160. a) Schnurr M, Witte C, Schröder L. Biophys J. 2014; 106:1301–1308. [PubMed: 24655505] b) 
Schnurr, M., Witte, C., Schröder, L. Chapter 16: Caged Xenon in Phospholipid Membrane 
Environments. Meersmann, T., Brunner, E., editors. 2015. p. 288-300.
161. Jeong K, Slack CC, Vassiliou CC, Dao P, Gomes MD, Kennedy DJ, Truxal AE, Sperling LJ, 
Francis MB, Wemmer DE. ChemPhysChem. 2015; 16:3573–3577. [PubMed: 26376768] 
162. Zamberlan F, Lesbats C, Rogers NJ, Krupa JL, Pavlovskaya GE, Thomas NR, Faas HM, 
Meersmann T. ChemPhysChem. 2015; 16:2294–2298. [PubMed: 26083583] 
163. a) Wang Y, Dmochowski IJ. Chem Commun. 2015; 51:8982–8985.b) Kunth M, Witte C, Hennig 
A, Schroder L. Chem Sci. 2015; 6:6069–6075.
164. Schnurr M, Sloniec - Myszk J, Döpfert J, Schröder L, Hennig A. Angew Chem Int Ed. 2015; 
54:13444–13447.
165. Wang Y, Roose BW, Palovcak EJ, Carnevale V, Dmochowski IJ. Angew Chem Int Ed. 2016; 
55:8984–8987.
166. Finbloom JA, Slack CC, Bruns CJ, Jeong K, Wemmer DE, Pines A, Francis MB. Chem Commun. 
2016; 52:3119–3122.
167. Stevens TK, Palaniappan KK, Ramirez RM, Francis MB, Wemmer DE, Pines A. Magn Reson 
Med. 2013; 69:1245–1252. [PubMed: 22791581] 
168. Meldrum T, Seim KL, Bajaj VS, Palaniappan KK, Wu W, Francis MB, Wemmer DE, Pines A. J 
Am Chem Soc. 2010; 132:5936–5937. [PubMed: 20392049] 
169. Schnurr M, Sydow K, Rose H, Dathe M, Schroder L. Adv Healthc Mater. 2015; 4:40–45. 
[PubMed: 24985966] 
170. Stevens TK, Ramirez RM, Pines A. J Am Chem Soc. 2013; 135:9576–9579. [PubMed: 
23742228] 
171. Shapiro M, Ramirez R, Sperling L, Sun G, Sun J, Pines A, Schaffer D, Bajaj V. Nat Chem. 2014; 
6:630–635.
Barskiy et al. Page 35
Chemistry. Author manuscript; available in PMC 2018 January 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
172. Bai Y, Wang Y, Goulian M, Driks A, Dmochowski IJ. Chem Sci. 2014; 5:3197–3203. [PubMed: 
25089181] 
173. Witte C, Kunth M, Rossella F, Schroder L. J Chem Phys. 2014:140.
174. Zaiss M, Schnurr M, Bachert P. J Chem Phys. 2012; 136:144106. [PubMed: 22502500] 
175. Kunth M, Witte C, Schroder L. J Chem Phys. 2014; 141:194202. [PubMed: 25416884] 
176. Kunth M, Witte C, Schroder L. NMR Biomed. 2015; 28:601–606. [PubMed: 25900330] 
177. Dopfert J, Witte C, Kunth M, Schroder L. Contrast Media Mol Imaging. 2014; 9:100–107. 
[PubMed: 24470299] 
178. a) Dopfert J, Witte C, Schroder L. ChemPhysChem. 2014; 15:261–264. [PubMed: 24408772] b) 
Boutin C, Léonce E, Brotin T, Jerschow A, Berthault P. J Phys Chem Lett. 2013; 4:4172–4176. 
[PubMed: 24563724] 
179. a) Louie AY, Hüber MM, Ahrens ET, Rothbächer U, Moats R, Jacobs RE, Fraser SE, Meade TJ. 
Nat Biotechnol. 2000; 18:321–325. [PubMed: 10700150] b) Weissleder R, Moore A, Mahmood 
U, Bhorade R, Benveniste H, Chiocca EA, Basilion JP. Nat Med. 2000; 6:351–354. [PubMed: 
10700241] c) Bartelle BB, Berríos-Otero CA, Rodriguez JJ, Friedland AE, Aristizábal O, 
Turnbull DH. Circul Res. 2012; 110:938–947.d) Patrick PS, Hammersley J, Loizou L, Kettunen 
MI, Rodrigues TB, Hu DE, Tee SS, Hesketh R, Lyons SK, Soloviev D. Proc Natl Acad Sci USA. 
2014; 111:415–420. [PubMed: 24347640] e) Westmeyer, Gil G., Emer, Y., Lintelmann, J., 
Jasanoff, A. Chem Biol. 2014; 21:422–429. [PubMed: 24613020] 
180. a) Genove G, DeMarco U, Xu H, Goins WF, Ahrens ET. Nat Med. 2005; 11:450–454. [PubMed: 
15778721] b) Cohen B, Dafni H, Meir G, Harmelin A, Neeman M. Neoplasia. 2005; 7:109–117. 
[PubMed: 15802016] 
181. Zurkiya O, Chan AWS, Hu X. Magn Reson Med. 2008; 59:1225–1231. [PubMed: 18506784] 
182. Bartelle BB, Mana MD, Suero - Abreu GA, Rodriguez JJ, Turnbull DH. Magn Reson Med. 2015; 
74:1750–1757. [PubMed: 25522343] 
183. Weissleder R, Simonova M, Bogdanova A, Bredow S, Enochs WS, Bogdanov JA. Radiology. 
1997; 204:425–429. [PubMed: 9240530] 
184. Shapiro M, Westmeyer G, Romero P, Szablowski J, Kuster B, Shah A, Otey C, Langer R, Arnold 
F, Jasanoff A. Nat Biotechnol. 2010; 28:264–U120. [PubMed: 20190737] 
185. Gilad AA, McMahon MT, Walczak P, Winnard PT, Raman V, van Laarhoven HW, Skoglund CM, 
Bulte JW, van Zijl PC. Nat Biotechnol. 2007; 25:217–219. [PubMed: 17259977] 
186. Bar-Shir A, Liu G, Chan KW, Oskolkov N, Song X, Yadav NN, Walczak P, McMahon MT, van 
Zijl PC, Bulte JW. ACS Chem Biol. 2013; 9:134–138. [PubMed: 24138139] 
187. Mukherjee A, Wu D, Davis HC, Shapiro MG. bioRxiv. 2016:037515.
188. a) Kodibagkar VD, Yu J, Liu L, Hetherington HP, Mason RP. Magn Reson Imaging. 2006; 
24:959–962. [PubMed: 16916713] b) Liu L, Kodibagkar VD, Yu JX, Mason RP. The FASEB 
Journal. 2007; 21:2014–2019. [PubMed: 17351127] c) Jamin Y, Gabellieri C, Smyth L, Reynolds 
S, Robinson SP, Springer CJ, Leach MO, Payne GS, Eykyn TR. Magn Reson Med. 2009; 
62:1300–1304. [PubMed: 19780183] 
189. a) Chen AP, Hurd RE, Gu Y-p, Wilson DM, Cunningham CH. NMR Biomed. 2011; 24:514–520. 
[PubMed: 21674653] b) Patrick PS, Kettunen MI, Tee SS, Rodrigues TB, Serrao E, Timm KN, 
McGuire S, Brindle KM. Magn Reson Med. 2015; 73:1401–1406. [PubMed: 24733406] 
190. a) Koretsky AP, Traxler BA. FEBS Lett. 1989; 243:8–12. [PubMed: 2646148] b) Koretsky AP, 
Brosnan MJ, Chen LH, Chen JD, Van Dyke T. Proc Natl Acad Sci USA. 1990; 87:3112–3116. 
[PubMed: 2326269] c) Walter G, Barton ER, Sweeney HL. Proc Natl Acad Sci. 2000; 97:5151–
5155. [PubMed: 10805778] 
191. a) Srivastava AK, Kadayakkara DK, Bar-Shir A, Gilad AA, McMahon MT, Bulte JW. Dis Model 
Mech. 2015; 8:323–336. [PubMed: 26035841] b) Gilad AA, Ziv K, McMahon MT, Van Zijl PC, 
Neeman M, Bulte JW. J Nucl Med. 2008; 49:1905–1908. [PubMed: 18997049] c) Jasanoff A. 
Curr Opin Neurobiol. 2007; 17:593–600. [PubMed: 18093824] 
192. Prange T, Schiltz M, Pernot L, Colloc’h N, Longhi S, Bourguet W, Fourme R. Proteins: Struct, 
Funct, Bioinf. 1998; 30:61–73.
Barskiy et al. Page 36
Chemistry. Author manuscript; available in PMC 2018 January 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
193. a) Locci E, Dehouck Y, Casu M, Saba G, Lai A, Luhmer M, Reisse J, Bartik K. J Magn Reson. 
2001; 150:167–174. [PubMed: 11384176] b) Cherubini A, Bifone A. Prog Nucl Magn Reson 
Spectrosc. 2003; 42:1–30.
194. Tilton R Jr, Kuntz I Jr. Biochemistry. 1982; 21:6850–6857. [PubMed: 7159568] 
195. a) Pfeifer F. Nat Rev Microbiol. 2012; 10:705–715. [PubMed: 22941504] b) Walsby A. Microbiol 
Rev. 1994; 58:94–144. [PubMed: 8177173] 
196. a) Harel E, Schröder L, Xu S. Annu Rev Anal Chem. 2008; 1:133–163.b) van Zijl P, Yadav NN. 
Magn Reson Med. 2011; 65:927–948. [PubMed: 21337419] 
197. Shapiro MG, Goodwill PW, Neogy A, Yin M, Foster FS, Schaffer DV, Conolly SM. Nat Nano. 
2014; 9:311–316.
198. Lu GJ, Farhadi A, Szablowski JO, Barnes SR, Lakshmanan A, Bourdeau RW, Shapiro MG. in 
preparation. 
199. Wang Y, Roose BW, Palovcak EJ, Carnevale V, Dmochowski IJ. Angew Chem Int Ed. 2016; doi: 
10.1002/anie.201604055
200. Farkas, A. Ortho-hydrogen, para-Hydrogen, and Heavy Hydrogen. Cambridge University Press; 
Cambridge, UK: 1935. 
201. a) Buljubasich L, Franzoni MB, Munnemann K. Top Curr Chem. 2013; 338:33–74. [PubMed: 
23536243] b) Green R, Adams R, Duckett S, Mewis R, Williamson D, Green G. Prog Nucl Magn 
Reson Spectrosc. 2012; 67:1–48. [PubMed: 23101588] 
202. a) Feng B, Coffey A, Colon R, Chekmenev E, Waddell K. J Magn Reson. 2012; 214:258–262. 
[PubMed: 22188975] b) Hövener JB, Bar S, Leupold J, Jenne K, Leibfritz D, Hennig J, Duckett 
SB, von Elverfeldt D. NMR Biomed. 2013; 26:124–131. [PubMed: 22833391] c) Kadlecek S, 
Vahdat V, Nakayama T, Ng D, Emami K, Rizi R. NMR Biomed. 2011; 24:933–942. [PubMed: 
21845739] 
203. a) Seidler PF, Bryndza HE, Frommer JE, Stuhl LS, Bergman RG. Organometallics. 1983; 2:1701–
1705.b) Hommeltoft SI, Berry DH, Eisenberg R. J Am Chem Soc. 1986; 108:5345–5347.
204. Pravica MG, Weitekamp DP. Chem Phys Lett. 1988; 145:255–258.
205. Bowers CR. eMagRes. 2007; emrstm9780470030489. doi: 10.1002/9780470034590
206. Levitt, M. Spin Dynamics: Basics of Nuclear Magnetic Resonance. John Wiley & Sons; 2001. 
207. Kubas Gregory J. Acc Chem Res. 1988; 21:120–128.
208. Reineri F, Aime S, Gobetto R, Nervi C. J Chem Phys. 2014; 140:094307. [PubMed: 24606361] 
209. Horiuti I, Polanyi M. T Faraday Soc. 1934; 30:1164–1172.
210. Eichhorn A, Koch A, Bargon J. J Mol Catal A. 2001; 174:293–295.
211. Lilburn DM, Pavlovskaya GE, Meersmann T. J Magn Reson. 2013; 229:173–186. [PubMed: 
23290627] 
212. a) Zhou R, Zhao E, Cheng W, Neal L, Zheng H, Quinones R, Hagelin-Weaver H, Bowers C. J Am 
Chem Soc. 2015; 137:1938–1946. [PubMed: 25629434] b) Balu AM, Duckett SB, Luque R. 
Dalton Trans. 2009:5074–5076. [PubMed: 19562165] 
213. Kovtunov K, Zhivonitko V, Skovpin I, Barskiy D, Salnikov O, Koptyug I. J Phys Chem C. 2013; 
117:22887–22893.
214. Kovtunov K, Barskiy D, Shchepin R, Coffey A, Waddell K, Koptyug I, Chekmenev E. Anal 
Chem. 2014; 86:6192–6196. [PubMed: 24918975] 
215. Zhivonitko VV, Kovtunov KV, Skovpin IV, Barskiy DA, Salnikov OG, Koptyug IV. 
Understanding Organometallic Reaction Mechanisms and Catalysis. 2014:145–186.
216. a) Kovtunov K, Barskiy D, Coffey A, Truong M, Salnikov O, Khudorozhkov A, Inozemtseva E, 
Prosvirin I, Bukhtiyarov V, Waddell K, Chekmenev E, Koptyug I. Chem Eur J. 2014; 20:11636–
11639. [PubMed: 24961814] b) Zhao E, Zheng H, Ludden K, Xin Y, Hagelin-Weaver H, Bowers 
C. ACS Catal. 2016; 6:974–978.c) Kovtunov K, Barskiy D, Salnikov O, Burueva D, 
Khudorozhkov A, Bukhtiyarov A, Prosvirin I, Gerasimov E, Bukhtiyarov V, Koptyug I. 
ChemCatChem. 2015; 7:2581–2584.
217. Barskiy D, Salnikov O, Kovtunov K, Koptyug I. J Phys Chem A. 2015; 119:996–1006. [PubMed: 
25587942] 
Barskiy et al. Page 37
Chemistry. Author manuscript; available in PMC 2018 January 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
218. Corma A, Salnikov O, Barskiy D, Kovtunov K, Koptyug I. Chem Eur J. 2015; 21:7012–7015. 
[PubMed: 25754067] 
219. Haase A, Frahm J, Matthaei D, Hanicke W, Merboldt K-D. J Magn Reson. 1986; 67:258–266.
220. Robson MD, Gatehouse PD, Bydder M, Bydder GM. J Comput Assist Tomogr. 2003; 27:825–
846. [PubMed: 14600447] 
221. Kovtunov KV, Romanov AS, Salnikov OG, Barskiy DA, Chekmenev EY, Koptyug IV. 
Tomography. 2016; 2:49–55. [PubMed: 27478870] 
222. Kovtunov K, Truong M, Barskiy D, Salnikov O, Bukhtiyarov V, Coffey A, Waddell K, Koptyug I, 
Chekmenev E. J Phys Chem C. 2014; 118:28234–28243.
223. Harel E. Lab Chip. 2009; 9:17–23. [PubMed: 19209329] 
224. Moulé AJ, Spence MM, Han S-I, Seeley JA, Pierce KL, Saxena S, Pines A. Proc Natl Acad Sci 
USA. 2003; 100:9122–9127. [PubMed: 12876195] 
225. a) Seeley JA, Han SI, Pines A. J Magn Reson. 2004; 167:282–290. [PubMed: 15040984] b) Zhou 
X, Graziani D, Pines A. Proc Natl Acad Sci USA. 2009; 106:16903–16906. [PubMed: 19805177] 
226. Hilty C, McDonnell EE, Granwehr J, Pierce KL, Han S-I, Pines A. Proc Natl Acad Sci USA. 
2005; 102:14960–14963. [PubMed: 16214884] 
227. Granwehr J, Harel E, Han S, Garcia S, Pines A, Sen PN, Song Y-Q. Phys Rev Lett. 2005; 
95:075503. [PubMed: 16196792] 
228. Harel E, Granwehr J, Seeley JA, Pines A. Nat Mater. 2006; 5:321–327. [PubMed: 16518395] 
229. Telkki V, Saunavaara J, Jokisaari J. J Magn Reson. 2010; 202:78–84. [PubMed: 19857978] 
230. Telkki V, Hilty C, Garcia S, Harel E, Pines A. J Phys Chem B. 2007; 111:13929–13936. 
[PubMed: 18001086] 
231. a) Telkki V, Zhivonitko V, Ahola S, Kovtunov K, Jokisaari J, Koptyug I. Angew Chem Int Ed. 
2010; 49:8363–8366.b) Telkki V, Zhivonitko V. J Magn Reson. 2011; 210:238–245. [PubMed: 
21459639] c) Zhivonitko V, Telkki V, Koptyug I. Angew Chem Int Ed. 2012; 51:8054–8058.
232. a) Zhivonitko V, Telkki V, Leppaniemi J, Scotti G, Franssila S, Koptyug I. Lab Chip. 2013; 
13:1554–1561. [PubMed: 23435499] b) Telkki V, Zhivonitko V, Selent A, Scotti G, Leppaniemi 
J, Franssila S, Koptyug I. Angew Chem Int Ed. 2014; 53:11289–11293.
233. Levitt M. Annu Rev Phys Chem. 2012; 63:89–105. [PubMed: 22224703] 
234. Zhivonitko V, Kovtunov K, Chapovsky P, Koptyug I. Angew Chem Int Ed. 2013; 52:13251–
13255.
235. Tal A, Frydman L. Prog Nucl Magn Reson Spectrosc. 2010; 57:241–292. [PubMed: 20667401] 
236. Ahola S, Zhivonitko V, Mankinen O, Zhang G, Kantola A, Chen H, Hilty C, Koptyug I, Telkki V. 
Nat Commun. 2015; 6:8363. [PubMed: 26381101] 
237. a) Ahola S, Telkki V. ChemPhysChem. 2014; 15:1687–1692. [PubMed: 24634359] b) King J, Lee 
V, Ahola S, Telkki V, Meldrum T. Angew Chem Int Ed. 2016; 55:5040–5043.
238. a) Kuzma NN, Hakansson P, Pourfathi M, Ghosh RK, Kara H, Kadlecek SJ, Pileio G, Levitt MH, 
Rizi RR. J Magn Reson. 2013; 234:90–94. [PubMed: 23851025] b) Ghosh RK, Kuzma NN, 
Kadlecek SJ, Rizi RR. Magn Reson Med. 2016; 75:1822–1830. [PubMed: 25976973] 
239. Freeman MS, Emami K, Driehuys B. Phys Rev A. 2014; 90:023406. [PubMed: 25400489] 
Biographies
Barskiy et al. Page 38
Chemistry. Author manuscript; available in PMC 2018 January 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Boyd M. Goodson graduated from Princeton University in 1995 (thesis research with 
Warren Warren and Herschel Rabitz) and earned his PhD in chemistry in 1999 with 
Alexander Pines at the University of California, Berkeley/LBNL. Following postdoctoral 
work with Ahmed Zewail at Caltech, in 2002 Goodson joined the faculty at Southern Illinois 
University Carbondale and was promoted to full professor in 2014. His research and 
teaching have been recognized by an NSF CAREER award, Research Innovation and 
Cottrell Scholar Awards from the Research Corporation for Science Advancement, the 
ORAU Powe Junior Faculty Award, and the Kaplan Award for Research, Sigma Xi Society 
(SIUC Chapter). Goodson’s research interests concern magnetic resonance and optical 
spectroscopies, NMR/MRI sensitivity enhancement, and hyperpolarization.
Matthew S. Rosen received his PhD in Physics at the University of Michigan in 2001, where 
he developed the first 129Xe high-volume hyperpolarizer for in vivo use, and with it 
demonstrated the first use of 129Xe as a MRI tracer in vivo. His career bridges the spectrum 
from fundamental physics to applied bioimaging work. He an Assistant Professor of 
Radiology at Harvard Medical School and the Director of the Low-Field MRI and 
Hyperpolarized Media Laboratory at the MGH/Martinos Center for Biomedical Imaging. He 
currently leads an effort to develop tools and techniques for robust ultra-low-magnetic-field 
implementations of MRI.
Dr. Danila A. Barskiy studied Chemistry in Novosibirsk State University where he obtained 
PhD in 2015. He is currently pursuing his research interests as a Postdoctoral Fellow at the 
Vanderbilt University Institute of Imaging Science in the laboratory of Prof. Eduard 
Chekmenev. His research interests include spin dynamics and chemical kinetics of 
parahydrogen-based nuclear spin hyperpolarization techniques (SABRE and PHIP) and 
applications of these techniques for NMR spectroscopy and imaging of biomedical and 
industrial processes.
Barskiy et al. Page 39
Chemistry. Author manuscript; available in PMC 2018 January 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Prof. Dmitry Mikhaylov studied applied physics at the National Research Nuclear 
University MEPHI (NRNU MEPHI). He got his PhD in 2011 under the guidance of Prof. M. 
Ivanov. In 2012 he became the head of Engineering Science Center of NRNU MEPHI, one 
of the biggest R&D centers in Russia. In 2012 he received one of the biggest Russian State 
research grants for research in the area of endoscopy. In 2013, he started collaboration with 
Vanderbilt University for research in field of endoscopy and nanomaterials. In 2015, he 
received an award from Russian Airspace Agency to conduct research in gravity free 
biological processes. In 2016, he moved to China to continue research.
Panayiotis Nikolaou studied Chemistry with a primary focus on (i) developing and applying 
new technologies to understand and improve hyperpolarized 129Xe production and (ii) 
studying the host-guest dynamics of 29Xe–cryptophane inclusion complexes at Southern 
Illinois University Carbondale (under the guidance of Prof. Boyd M. Goodson), where he 
earned his PhD in 2010. He is currently a Post-Doctoral fellow with Prof. Eduard 
Chekmenev at Vanderbilt, where he has designed and built two automated clinical-scale 
xenon polarizers. Current Research interests include the development of fully-automated 
xenon hyperpolarizer technology, hyperpolarized contrast agents, and their biomedical 
application in MR.
Eduard Y. Chekmenev, b 1977, PhD in Physical Chemistry (supervisor Prof. Richard J. 
Wittebort) 2003, University of Louisville, KY, USA. Postdoctoral Fellow at NHMFL to 
Barskiy et al. Page 40
Chemistry. Author manuscript; available in PMC 2018 January 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
work on structural biology of membrane proteins in Tallahassee, FL, USA (with Prof. 
Timothy Cross) and in NMR hyperpolarization at Caltech (with Prof. Daniel P. Weitekamp) 
and hyperpolarized in vivo imaging at HMRI (with Dr. Brian D. Ross). In 2009, Dr. 
Chekmenev started his hyperpolarization program at Vanderbilt University Institute of 
Imaging Science (VUIIS), and he was tenured in 2015. In 2016, he was elected as a 
Professor of the Russian Academy of Sciences. Research interests include development of 
methods of hyperpolarization and their Biomedical and industrial applications.
Shahideh Safavi studied Medicine at St George’s University of London, graduating in 2008. 
She undertook her general medicine training in London, followed by specialist training in 
respiratory medicine in London and Nottingham. She is currently pursuing her research 
interests at University of Nottingham, as a clinical research fellow, under the supervision of 
Prof. Ian Hall and Dr. Michael Barlow. Her research is focused on development and use of 
novel functional MRI techniques in respiratory medicine.
Michael Barlow studied Physics at Essex University where he obtained his Ph.D in the study 
of hot electron transport in semiconductor quantum wells. His interest in optical pumping 
arose from work on helium magnetometers when he was instrument manager for the NASA 
Cassini MAG team. This work continues to the present day with optical pumping and 
Raman techniques to explore spin exchange optical pumping for the production of 
hyperpolarized xenon. He is currently lead physicist for the Nottingham xenon Lung 
imaging team.
Barskiy et al. Page 41
Chemistry. Author manuscript; available in PMC 2018 January 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Professor Ian Hall is currently the Boots’ Professor of Therapeutics and Director of the 
Centre for Biomolecular Sciences at the University of Nottingham. His main clinical interest 
is in respiratory medicine. He completed his clinical studies at the University of Oxford 
before moving to Nottingham for specialist and research training. Subsequently he was an 
MRC travelling fellow at the University of Pennsylvania and National Asthma Campaign 
Senior Research Fellow back in Nottingham. Current research interests include the genetic 
basis of lung disease and novel imaging approaches.
Rosa Tamara Branca studied Physics at the University of Rome La Sapienza, where she 
obtained her Bachelors of Science and Masters degree in 2002. In 2006 she obtained her 
PhD in Biophysics under the guidance of Dr. B. Maraviglia and Dr. W. Warren while 
studying non-linear MR effects due to dipolar-dipolar interactions and radiation damping. In 
2006 she moved to Duke University, first as a Post-Doctoral Fellow and then as an Assistant 
Research Professor (2009). She began working with hyperpolarized gases in 2009, while 
working on a project to detect targeted lung metastases with HP Helium. In 2012 she moved 
to the University of North Carolina at Chapel Hill, where she holds a faculty appointment in 
the Department of Physics and Astronomy and in the Biomedical Research Imaging Center. 
Her current research interests include applications of hyperpolarized gases in lung and 
brown fat imaging.
Barskiy et al. Page 42
Chemistry. Author manuscript; available in PMC 2018 January 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Leif Schröder studied Physics in Göttingen and Heidelberg where he obtained a PhD in 
Physics while being affiliated with the German Cancer Research Center to investigate the 
quantum mechanical fine structure of in vivo NMR spectra. His subsequent stay at the 
University of California at Berkeley and Lawrence Berkeley National Laboratory was 
supported by an Emmy Noether fellowship from the German Research Foundation to work 
hyperpolarized xenon biosensors. He is a co-developer of the Hyper-CEST technique for 
which he received national and international prizes, including the IUPAP Young Scientist 
Award in Medical Physics. He further received an Emmy Noether fellowship to start his own 
group at the FMP, Berlin, where he also managed the ERC Project BiosensorImaging and is 
currently heading the Molecular Imaging Group.
Mikhail G. Shapiro is an Assistant Professor of Chemical Engineering and a Heritage 
Principal Investigator at the California Institute of Technology. His laboratory works on 
biomolecular technologies for non-invasive imaging and control of biological function. He 
received his PhD in Biological Engineering from MIT and held post-doctoral fellowships at 
the University of Chicago and the University of California, Berkeley. He has pioneered 
protein-based MRI sensors of neurotransmission, reporter genes for several forms of MRI, 
including xenon and diffusion, and genetically encoded reporters for ultrasound. His awards 
include the Burroughs Wellcome Career Award, the DARPA Young Faculty Award, the Pew 
Biomedical Scholarship and the Technology Review’s TR35 list of the top innovators under 
age 35.
Dr. George J. Lu obtained his B.S. degree at University of Alberta, Canada, where he 
worked with Prof. Brian Sykes and Prof. Michael James on protein NMR and X-ray 
crystallography. He received his Ph.D. at the University of California, San Diego (UCSD), 
where he studied solid-state NMR methodology and membrane protein structural biology 
with Prof. Stanley Opella. He is currently a postdoctoral fellow at Caltech with Prof. 
Mikhail Shapiro, and his research applies the technique of protein engineering to the 
development of MRI contrast agents and new imaging and therapeutic methods.
Barskiy et al. Page 43
Chemistry. Author manuscript; available in PMC 2018 January 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Dr. Aaron M. Coffey conducted undergraduate studies in Electrical Engineering at the 
University of Arizona, Tucson. He completed a PhD in Biomedical Engineering in 2014 at 
Vanderbilt University under the guidance of Prof. Eduard Chekmenev in the area of 
hyperpolarized and low-field NMR and MRI, where he continued as a postdoctoral fellow. 
He recently received the Ruth L. Kirschstein postdoctoral fellowship 1F32EB021840-01 for 
‘Ultra-fast molecular MRI of human adipose tissue with hyperpolarized xenon-129 contrast 
agent.’ His research interests include advancing MR detection hardware and utilizing 
hyperpolarization techniques to enable MR contrast agents for molecular imaging and high 
sensitivity spectroscopic NMR studies.
Prof. Igor V. Koptyug received his PhD degree in 1991; in 1992–1995 he was a postdoctoral 
researcher in the photochemistry group of Professor N. J. Turro (Columbia University, New 
York). He earned his Dr. Sci. (Habilitation) degree in catalysis in 2003 and a title of 
Professor in 2006; currently, he is the head of the Laboratory of Magnetic Resonance 
Microimaging at the International Tomography Center, Siberian Branch of the Russian 
Academy of Sciences, Novosibirsk. His research interests include signal enhancement in 
NMR and applications of NMR and MRI in catalysis and biological studies in vivo and in 
vitro.
Dr. Kirill V. Kovtunov studied chemistry at the Novosibirsk State University, Russia. He 
completed a PhD in Physical Chemistry in 2008 at the International Tomography Center 
Barskiy et al. Page 44
Chemistry. Author manuscript; available in PMC 2018 January 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
under the supervision of Prof. Igor Koptyug in the area of utilization of parahydrogen in 
heterogeneous processes, where he obtained heterogeneous PHIP effects for the first time. 
His research interests include heterogeneous catalysis and utilization of parahydrogen-
induced polarization techniques to produce highly polarized contrast agents for NMR/MRI 
and mechanistic studies of heterogeneous reactions involving hydrogen. Currently, he is a 
senior scientific researcher in the group of Prof. Igor Koptyug.
Valerii I. Bukhtiyarov received his PhD degree in 1989. In 1993, Valeriy I. Bukhtiyarov held 
a post-doc position at University of Wales College of Cardiff (UK) supervised by Professor 
M. Wyn Roberts. He earned his Dr. Sci. (Habilitation) degree in catalysis in 1998 and a title 
of Professor in 2003. Since 2000, he is a head of the Surface Science Laboratory in the 
Boreskov Institute of Catalysis (BIC) of the Siberian Branch of the Russian Academy of 
Sciences, Novosibirsk; since July 2015, he is the director of BIC. The scientific interests of 
Valerii I. Bukhtiyarov include bridging between surface science and heterogeneous catalysis; 
application of physical methods to study adsorption and surface chemical reactions, 
including in-situ measurements; and application of nanoscience approaches for modeling 
and study of heterogeneous catalysts.
Oleg G. Salnikov completed his undergraduate studies in chemistry at Novosibirsk State 
University in 2014 and continued there as a PhD student. In 2012, he started working on the 
HET-PHIP project in the group of Prof. Igor Koptyug at the International Tomography 
Center SB RAS under the supervision of Dr. Kirill Kovtunov. His research interests include 
application of PHIP for mechanistic studies of heterogeneous catalytic reactions and 
development of MR contrast agents using HET-PHIP.
Barskiy et al. Page 45
Chemistry. Author manuscript; available in PMC 2018 January 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Ville-Veikko Telkki studied physics at the University of Oulu, Finland. He completed his 
PhD studies in 2006 under the guidance of Prof. Jukka Jokisaari. In 2005, before the final 
dissertation, he joined the research group of Prof. Alex Pines in UC Berkeley, concentrating 
on remote detection MRI. In 2007, he returned back to University of Oulu. Currently, he is a 
Research Fellow of Academy of Finland, and he is leading the Experimental NMR Research 
Group, focusing on the development and application of advanced NMR methods for 
materials research.
Dr. Vladimir V. Zhivonitko graduated from Novosibirsk State University, Russia, in 2005, 
where he studied chemistry. In the same year he started his PhD studies under supervision of 
Prof. Igor V. Koptyug at the International Tomography Center SB RAS. In 2008 he defended 
his PhD thesis concerning MRI of nonlinear chemical processes in model catalytic reactors. 
Thereafter, he joined the HET-PHIP project conducted in Prof. Koptyug’s lab as a 
postdoctoral researcher. His interests include basic NMR research with hyperpolarized 
substances, development of catalytic systems for PHIP and NMR micro-imaging of catalytic 
reactors. Currently, he works as a senior scientific researcher at the same location.
Barskiy et al. Page 46
Chemistry. Author manuscript; available in PMC 2018 January 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Schematic representations of SEOP.[2b, 4] (a) SEOP cell containing a noble gas (here, Xe), 
buffer gases (e.g. N2), and a small quantity of vaporized alkali metal (here, Rb); the cell is 
irradiated by circularly polarized laser light that can be absorbed by the alkali metal atoms. 
(b) The first step of SEOP: in order to conserve angular momentum, photon absorption 
results in selective population depletion from one Rb ground electronic state (neglecting Rb 
nuclear spin for simplicity). Although gas-phase collisions work to equalize the excited-state 
populations (and hence, the ground-state repopulation rates), continuous depletion of one 
state by the laser leaves the AM vapor electronically spin-polarized. (c) The second step of 
SEOP: Gas-phase collisions occasionally allow spin order to be transferred from the AM 
atom electrons to the noble gas nuclei via Fermi contact hyperfine interactions, thereby 
hyperpolarizing the noble gas over time. Reproduced with permission from Ref. [36] © John 
Wiley & Sons, Ltd., 2015.
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Figure 2. 
129Xe-MRI of a healthy volunteer. a) Coronal plane 25 mm slice 129Xe-MR ventilation 
image of a healthy adult male, with 129Xe appearing bright. The upper airways are 
delineated. b) Coronal plane 25 mm slice fused 129Xe-MR ventilation and proton co-
registration image, with 129Xe appearing green. The two black regions pointed out in the 
fused image (yellow arrows) are due to a diaphragmatic eventration and pulmonary 
vasculature, clearly defined on the fused image (blue arrows). J. Thorpe, B. Haywood, M. 
Barlow, S. Safavi & I. Hall - University of Nottingham (Unpublished work).
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Figure 3. 
ADC map of a healthy volunteer and a patient with COPD. a) Healthy volunteer with a low 
mean ADC of 0.037±0.021 cm2/s, indicating normal alveolar microstructure. b) Patient with 
COPD with high ADC values (0.068±0.028 cm2/s) in the parenchyma, indicating alveolar 
destruction. Reproduced with permission from Ref. [96] © John Wiley & Sons, Ltd., 2011.
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Figure 4. 
129Xe NMR spectra recorded from two healthy volunteers. Two dotted lines have been 
placed to represent the expected dissolved state peaks, the left most line representing the 
expected ~196 ppm lung parenchyma peak, and the right most line representing the expected 
216 ppm red blood cell peak. S. Hardy, B. Haywood, M. Barlow, S. Safavi & I. Hall - 
University of Nottingham (Unpublished work).
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Figure 5. 
129Xe brown adipose tissue (BAT) temperature map overlaid on a sagittal 1H image. These 
temperature maps were obtained by using the lipid-dissolved xenon signal as a temperature 
probe. The temperature coefficient of the lipid-dissolved xenon chemical shift was measured 
to be −0.2 ppm/°C.
Barskiy et al. Page 51
Chemistry. Author manuscript; available in PMC 2018 January 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 6. 
Caged Xe biosensor concept, and Hyper-CEST detection. a) Different Xe hosts confer 
different chemical shifts to the bound atoms that enable readout at distinct resonance 
frequencies. b) Xe inside a molecular host changes its resonance frequency upon binding to 
a target structure. c) Selective Hyper-CEST saturation at one of these frequencies causes a 
cloud of depolarized Xe around the respective host. The reduced signal from free Xe 
represents an amplified information from the small amount of cages. d) Sweeping the 
saturation pulse over a certain frequency range and subsequent observation of the 
magnetization from free Xe yields a Hyper-CEST spectrum for comparing the performance 
of different hosts.
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Figure 7. 
Gas vesicles as genetically encodable HyperCEST reporters detectable at pM 
concentrations. (a) Diagram of a gas vesicle: a hollow gas nano-compartment (solid shading) 
surrounded by a gas-permeable protein shell (ribbed shading). (b) Transmission electron 
micrographs of individual GVs purified from Halobacterium NRC-1 in their intact (left) and 
collapsed (right) state. (c) Diagram of 129Xe CEST between bulk aqueous solvent (left) and 
GVs (hexagons) either in isolation or inside a cell (gray). (d) Frequency-dependent 
saturation spectra for intact (red) and collapsed (black) GVs. (e) Saturation contrast image of 
a three-compartment phantom containing 400 pM GVs, 100 pM GVs and buffer. Reprinted 
by permission from Macmillan Publishers Ltd: Nature Chemistry,[171] copyright 2014.
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Figure 8. 
Parahydrogen conversion. Passage of H2 gas over a paramagnetic catalyst, given sufficient 
contact time, converts the ortho-H2 fraction to para-H2 fraction as a function of temperature.
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Figure 9. 
a) Molecular diagram of parahydrogen (para-H2) addition to the substrate performed with a 
homogeneous or heterogeneous catalyst. b) PASADENA effect: nuclear spin energy level 
diagram of para-H2 at high magnetic field (left), An AX spin system is formed upon 
pairwise addition of para-H2 to the unsaturated substrate at high magnetic field and 
corresponding 1H NMR spectrum (right). c) ALTADENA effect: nuclear spin energy level 
diagram of para-H2 at low magnetic field (left), An AB spin system is formed upon pairwise 
addition of para-H2 to the unsaturated substrate at low magnetic field, An AX spin system is 
obtained after adiabatic transfer of the reaction product from low to high magnetic field. The 
corresponding 1H NMR spectrum is shown at right.
Barskiy et al. Page 55
Chemistry. Author manuscript; available in PMC 2018 January 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 10. 
ALTADENA 1H NMR spectra of a gaseous stream during bubbling of parahydrogen (a) and 
normal H2 (b) through the solution of [Rh(I)(NBD)L]+BF4− in D2O at 70–80 °C. The broad 
signal labeled “H2” belongs to ortho-H2 gas: the resonances labeled with open circles 
correspond to norbornane. c) Diagram of the experimental setup with the NMR detection 
performed in the high field. Reprinted with permission from Kovtunov, K. V.; et al. Anal. 
Chem. 2014, 86, 6192.[214]
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Figure 11. 
Heterogeneous pairwise hydrogenation of propene to propane with para-H2 over Rh/TiO2 
catalyst with preservation of spin order of parahydrogen in the final HP product.
Barskiy et al. Page 57
Chemistry. Author manuscript; available in PMC 2018 January 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 12. 
(a) Schematic representation of the experimental setup for using PHIP to produce HP 
propane via heterogeneous hydrogenation of propene with parahydrogen. (b) 1H MRI 
FLASH image of HP propane flowing into a 10 mm NMR tube via 1/16 in. OD Teflon 
capillary. Note that the NMR tube is shown schematically and its length does not match the 
actual scale of the 2D MR image. Reprinted with permission from Kovtunov, K. V.; et al. 
Tomography 2016, 2, 49.[221]
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Figure 13. 
High-resolution 3D gradient echo (GRE) MRI at 4.7 T. a) 3D MRI of flowing HP propane 
gas (~20 mM concentration) with 0.5×0.5×0.5 mm3 spatial and 17.7 s temporal resolution 
and 32×32×32 mm3 field of view. b) The corresponding image of (stationary) thermally 
polarized tap water (55 M). Reprinted with permission from Kovtunov, K. V.; et al. J. Phys. 
Chem. C 2014, 118, 28234.[222]
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Figure 14. 
RD MRI of flow of HP 129Xe through a rock sample. (a) The rock sample is inside a large 
RF coil used to encode spatial information into spin coherences, and the signal is read out by 
a smaller and more sensitive coil around the outlet tubing, with optimized filling factor. (b) 
3D TOF images. The silhouettes represent the rock sample. TOF, i.e., the time instant the 
signal is detected after the encoding, is shown above the images. Reprinted with permission 
from Granwehr, J.; Harel, E.; Han, S.; Garcia, S.; Pines, A.; Sen, P. N.; Song, Y. Q. Phys. 
Rev. Lett. 95, 075503 (2005). Copyright (2005) by the American Physical Society.
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Figure 15. 
(a) RD MRI setup of a simplified microfluidic system consisting of a capillary leading 
through the encoding and detection coils. TOF RD MRI visualization of (a) HP propane and 
(b) water flow in the capillary (outlined in white), revealing much more extensive dispersion 
of liquid than that of gas molecules. TOF (ms) is shown at the bottom of the panels. The 
panels on the left are sums of the other panels.[231a]
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Figure 16. 
RD MRI of HP propane in microfluidic chips with (a) a widened channel in the middle part 
and (b) ladder-like channels (outlined in white). These images are the sum of the panels 
measured at different TOF instances, and they expose, e.g., manufacturing imperfections. 
Flow velocities extracted from TOF data are shown in (b). Reproduced with permission from 
Ref. [231a] © John Wiley & Sons, Ltd., 2010.
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Figure 17. 
RD MRI visualization of reaction progress inside a catalyst layer packed in a thin capillary. 
(a) Sample setup. 2D TOF images of HP propane resulting from the hydrogenation reaction 
in the reactors of (a) 800 and (b) 150 μm in diameter. The reactors are outlined by a white 
dashed line in the figures. TOF (ms) is shown at the bottom of the panels. The panels on the 
left are the sums of all other panels in each series.[231c]
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